Mammalian chemokine reagents

ABSTRACT

Novel chemokines from mammals, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said chemokines. Chemokine receptors are also provided. Methods of using said reagents and diagnostic kits are also provided.

This application is a division of U.S. patent application Ser. No.11/847,872; filed Aug. 30, 2007 which is a division of U.S. patentapplication Ser. No. 10/754,071, filed Jan. 7, 2004; which is a divisionof U.S. patent application Ser. No. 10/039,659, filed Jan. 3, 2002, nowU.S. Pat. No. 6,723,520; which is a division of U.S. patent applicationSer. No. 08/887,977, filed Jul. 3, 1997; which claims the benefit ofU.S. provisional patent application Nos. 60/048,593, filed Jun. 4, 1997;60/028,329, filed Oct. 11, 1996; and 60/021,664, filed Jul. 5, 1996;each of which is herein incorporated by reference in its entirety.

FIELD OF THE INVENTION

The present invention relates to compositions related to proteins whichfunction in controlling physiology, development, and/or differentiationof mammalian cells, e.g., cells of a mammalian immune system. Inparticular, it provides proteins and mimetics which regulate physiology,development, differentiation, and function of various cell types,including hematopoietic cells. It also provides receptor reagents forchemokine-like proteins.

BACKGROUND OF THE INVENTION

The circulating component of the mammalian circulatory system comprisesvarious cell types, including red and white blood cells of the erythroidor the myeloid cell lineages. See, e.g., Rapaport (1987) Introduction toHematology (2d ed.) Lippincott, Philadelphia, Pa.; Jandl (1987) Blood:Textbook of Hematology, Little, Brown and Co., Boston, Mass.; and Paul(ed.)(1993) Fundamental Immunology 3d ed, Raven Press, N.Y. Progressionthrough various stages of differentiation are regulated by varioussignals provided to the cells, often mediated through a class ofproteins known as the cytokines. Within this group of molecules as afurther group known as the chemoattractant cytokines, or chemokines.See, e.g., Schall (1994) “The Chemokines” in Thomson (ed.) The CytokineHandbook (2d ed.) Academic Press; and Schall and Bacon (1994) CurrentOpinion in Immunology 6:865-873.

Although the full spectrum of biological activities of the chemokineshas not been extensively investigated, chemoattractant effects arerecognized. The best known biological functions of these moleculesrelate to chemoattraction of leukocytes. However, new chemokines arebeing discovered, and their biological effects on the various cellsresponsible for immunological responses are topics of continued study.

Certain G-protein coupled receptors have also been characterized,presumably chemokine receptors. See, e.g., Samson, et al. (1996)Biochemistry 35:3362-3367; and Rapport, et al. (1996) J. LeukocyteBiology 59:18-23.

These observations indicate that other factors exist whose functions inhematopoiesis, immune development, and leukocyte trafficking wereheretofore unrecognized. These factors provide for biological activitieswhose spectra of effects are distinct from known differentiation,activation, or other signaling factors. The absence of knowledge aboutthe structural, biological, and physiological properties of theregulatory factors which regulate hematopoietic cell physiology in vivoprevents the modification of the effects of such factors. Thus, medicalconditions where regulation of the development or physiology of relevantcells is required remains unmanageable.

SUMMARY OF THE INVENTION

The present invention is based, in part, upon the discovery of new genesencoding chemokines, and new genes encoding various receptors forchemokines. It embraces agonists and antagonists of the chemokines. Inparticular, sequences of various chemokines, e.g., designated ThymusExpressed ChemoKine (TECK); MIP-3α; MIP-3β; and 7 transmembranereceptors, designated “dendritic cell receptor for chemokine” (DC CR)and “monocyte/dendritic cell receptor for chemokine” (M/DC CR); andmutations (muteins) of the respective natural sequences, fusionproteins, chemical mimetics, antibodies, and other structural orfunctional analogs are provided. It is also directed to isolated genesencoding respective proteins of the invention. Various uses of thesedifferent protein or nucleic acid compositions are also provided.

The present invention provides a substantially pure or isolatedpolypeptide comprising a segment exhibiting sequence homology to acorresponding portion of a mature TECK, MIP-3α, MIP-3β, DC CR, or M/DCCR, wherein the homology is at least about 70% identity and the portionis at least about 25 amino acids. Preferably, the protein furthercomprises a second segment exhibiting at least about 90% identity overat least 9 amino acids; or at least about 80% identity over at least 17amino acids. In other preferred embodiments, the polypeptide: is from awarm blooded animal selected from the group of birds and mammals,including a mouse or human; comprises a natural sequence from Tables 1through 5; exhibits a post-translational modification pattern distinctfrom a natural form of the polypeptide; is made by expression of arecombinant nucleic acid; comprises synthetic sequence; is detectablylabeled; is conjugated to a solid substrate; is conjugated to anotherchemical moiety; is a fusion protein; is in a denatured conformation,including detergent denaturation; further comprises an epitope tag; isan immunogenic polypeptide; has a defined homogeneous molecular weight;is useful as a carbon source; is an allelic variant of SEQ ID NO: 2, 4,6, 8, 10, or 12; is a 3-fold or less substituted form of a naturalsequence; is in a sterile composition; is in a buffered solution orsuspension; is in a regulated release device; comprises apost-translational modification; is in a cell; or is in a kit whichfurther comprises instructions for use or disposal of reagents therein.

In other aspects, the invention provides an isolated or recombinantnucleic acid encoding such protein, where the portion consists ofsequence from the coding region of SEQ ID NO: 1, 3, 5, 7, 9, or 11.Other aspects include such nucleic acids which: exhibit at least about80% identity to a natural cDNA encoding said segment; is in anexpression vector; further comprises a promoter; further comprises anorigin of replication; is from a natural source; is detectably labeled;comprises synthetic nucleotide sequence; is less than 6 kb; is from amammal; comprises a natural full length mature coding sequence; is in akit, which also comprises instructions for use or disposal of reagentstherein; is a specific hybridization probe for a gene encoding theprotein; is a PCR product; or is in a cell. The invention also providesa method of using a purified nucleic acid by expressing the nucleic acidto produce a protein.

Alternatively, the invention provides an isolated or recombinant nucleicacid which encodes at least eight consecutive residues of SEQ ID NO: 2,4, 6, 8, 10, or 12. Preferably, that nucleic acid encodes at least:twelve consecutive residues from SEQ ID NO: 2, and further comprises acoding sequence of at least 17 nucleotides from SEQ ID NO: 1; twelveconsecutive residues from SEQ ID NO: 4, and further comprises a codingsequence of at least 17 nucleotides from SEQ ID NO: 3; twelveconsecutive residues from SEQ ID NO: 6, and further comprises a codingsequence of at least 17 nucleotides from SEQ ID NO: 5; twelveconsecutive residues from SEQ ID NO: 8, and further comprises a codingsequence of at least 17 nucleotides from SEQ ID NO: 7; twelveconsecutive residues from SEQ ID NO: 10, and further comprises a codingsequence of at least 17 nucleotides from SEQ ID NO: 9; or twelveconsecutive residues from SEQ ID NO: 12, and further comprises a codingsequence of at least 17 nucleotides from SEQ ID NO: 11. In otherpreferred embodiments, the nucleic acid: exhibits at least about 80%identity to a natural cDNA encoding the segment; is in an expressionvector; further comprises a promoter; further comprises an origin ofreplication; encodes a 3-fold or less substituted sequence from anatural sequence; is from a natural source; is detectably labeled;comprises synthetic nucleotide sequence; is less than 6 kb; is from amammal; is attached to a solid substrate, including in a Southern orNorthern blot; comprises a natural full length coding sequence; is in acell; or is in a detection kit, which also comprises instructions foruse or disposal of reagents therein. Further embodiments include anucleic acid which hybridizes under stringent wash conditions of 55° C.and less than 150 mM salt to the nucleic acid; while preferredembodiments include those which exhibit at least about 85% identity overa stretch of at least about 30 nucleotides to a primate sequence of SEQID NO: 1, 3, 5, 7, 9, or 11; or where the identity is at least 90%; orthe stretch is at least 75 nucleotides; or where the identity is atleast 95%; or the stretch is at least 100 nucleotides.

In other embodiments, the invention provides a binding compoundcomprising an antigen binding fragment from an antibody which binds to amature TECK, MIP-3α, MIP-3β, DC CR, or M/DC CR protein. In variousembodiments, the binding compound is one wherein: the polypeptide is amouse or human protein; the antibody is raised against a mature peptidesequence of Tables 1 through 5; the antibody is a monoclonal antibody;the binding compound is attached to a solid substrate; the bindingcompound is in a sterile composition; the binding compound binds to adenatured antigen, including a detergent denatured antigen; the bindingcompound is detectably labeled; the binding compound is an Fv, Fab, orFab2 fragment; the binding compound is conjugated to a chemical moiety;the binding compound is in a detection kit which also comprisesinstructions for use or disposal of reagents therein.

The invention also provides a cell which makes the antibody.

The invention embraces methods of purifying a polypeptide using abinding compound to specifically separate said polypeptides from others;of generating an antigen-binding compound complex comprising the step ofcontacting a sample comprising the antigen to a sample comprising abinding compound; or of modulating physiology or development of a cellexpressing a receptor for a chemokine selected from TECK, MIP-3α, orMIP-3β; the method comprising contacting the cell with a compositioncomprising an agonist or mutein of said chemokine or an antibodyantagonist of the chemokine. In certain embodiments of the method, thecell is a macrophage, lymphocyte, or eosinophil; or the physiology is acellular calcium flux, a chemoattractant response, cellular morphologymodification responses, phosphoinositide lipid turnover, or an antiviralresponse. In other embodiments, the receptor is DC CR and the chemokineis MIP-3α, the physiology is pulmonary physiology, or the cell is aneosinophil.

DESCRIPTION OF THE DRAWINGS

FIGS. 1A-1B show chemotactic properties of mTECK recombinant protein.FIG. 1A shows migration of mouse thymocytes to recombinant mTECK andeffect of pertussis toxin. Chemotaxis assays were performed asdescribed. Recombinant mouse lymphotactin was used as a positivecontrol. Data are expressed as the mean of cell counts obtained fromthree separate experiments in duplicate ±SEM. In one experiment, cellswere pre incubated 1 h with 10 ng/ml pertussis toxin (PTX) prior to theassay. FIG. 1B shows migration of other leukocyte subsets to recombinantmTECK. Mouse splenic dendritic cells and mouse activated macrophageswere obtained. THP-1 human monocytic cells were used without or with a16 h activation with IFN-γ. Results are obtained as the mean of thechemotactic index from three separate experiments per cell type induplicate ±SD. The number of cells migrating to medium alone was greaterthan 40 cells per 5 high power fields in each experiment. RecombinantMIP-1α, was used as a positive control.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

OUTLINE

I. General

II. Purified Chemokines, Receptors

-   -   A. physical properties    -   B. biological properties

III. Physical Variants

-   -   A. sequence variants, fragments    -   B. post-translational variants        -   1. glycosylation        -   2. others

IV. Functional Variants

-   -   A. analogs; fragments        -   1. agonists        -   2. antagonists    -   B. mimetics        -   1. protein        -   2. chemicals    -   C. species variants

V. Antibodies

-   -   A. polyclonal    -   B. monoclonal    -   C. fragments, binding compositions

VI. Nucleic Acids

-   -   A. natural isolates; methods    -   B. synthetic genes    -   C. methods to isolate

VII. Making Chemokines, Receptors; Mimetics

-   -   A. recombinant methods    -   B. synthetic methods    -   C. natural purification

VIII. Uses

-   -   A. diagnostic    -   B. therapeutic

IX. Kits

-   -   A. nucleic acid reagents    -   B. protein reagents    -   C. antibody reagents

X. Receptors

I. General

The present invention provides DNA sequences encoding various mammalianproteins which exhibit structural properties characteristic of achemotactic cytokine, or chemokine. Other embodiments are directed tochemokine receptors. See, e.g., Lodi, et al. (1994) Science263:1762-1767; Gronenborn and Clore (1991) Protein Engineerinq4:263-269; Miller and Kranger (1992) Proc. Nat'l Acad. Sci. USA89:2950-2954; Matsushima and Oppenheim (1989) Cytokine 1:2-13; Stoeckleand Baker (1990) New Biol. 2:313-323; Oppenheim, et al. (1991) Ann. Rev.Immunol. 9:617-648; Schall (1991) Cytokine 3:165-183; and The CytokineHandbook Academic Press, NY. Mouse and human embodiments are describedherein.

Chemokines play an important role in immune and inflammatory responsesby inducing migration and adhesion of leukocytes. These small secretedmolecules are a growing superfamily of 8-14 kDa proteins characterizedby a conserved four cysteine motif. See, e.g., Schall (1991) Cytokine3:165-183; and Thomson (ed.) The Cytokine Handbook Academic Press, NY.Chemokines are secreted by activated leukocytes and act as achemoattractant for a variety of cells which are involved ininflammation. Besides chemoattractant properties, chemokines have beenshown to induce other biological responses, e.g., modulation of secondmessenger levels such as Ca⁺⁺; inositol phosphate pool changes (see,e.g., Berridge (1993) Nature 361:315-325 or Billah and Anthes (1990)Biochem. J. 269:281-291); cellular morphology modification responses;phosphoinositide lipid turnover; possible antiviral responses; andothers. Thus, the chemokines provided herein may, alone or incombination with other therapeutic reagents, have advantageouscombination effects.

Moreover, there are reasons to suggest that chemokines may have effectson other cell types, e.g., attraction or activation of monocytes,dendritic cells, T cells, eosinophils, and/or perhaps on basophilsand/or neutrophils. They may also have chemoattractive effects onvarious neural cells including, e.g., dorsal root ganglia neurons in theperipheral nervous system and/or central nervous system neurons.

Membrane proteins which contain seven transmembrane segments have beencharacterized as G-protein coupled receptors. Many of these receptorshave been characterized as receptors for chemokines, based in part onstructural features. Chemokine receptors are important in the signaltransduction mechanisms mediated by the chemokines. They are usefulmarkers for distinguishing cell populations, and have been implicated asspecific receptors for retroviral infections.

The chemokine superfamily was classically divided into two groupsexhibiting characteristic structural motifs, the Cys-X-Cys (C-X-C) andCys-Cys (C-C) families. These were distinguished on the basis of asingle amino acid insertion between the NH-proximal pair of cysteineresidues and sequence similarity. Typically, the C-X-C chemokines, i.e.,IL-8 and MGSA/Gro-α act on neutrophils but not on monocytes, whereas theC-C chemokines, i.e., MIP-1α and RANTES, are potent chemoattractants formonocytes and lymphocytes but not neutrophils. See, e.g., Miller, et al.(1992) Crit. Rev. Immunol. 12:17-46. A recently isolated chemokine,lymphotactin, does not belong to either group and may constitute a firstmember of a third chemokine family, the C family. Lymphotactin does nothave a characteristic CC or CXC motif, and acts on lymphocytes but notneutrophils and monocytes. See, e.g., Kelner et al. (1994) Science266:1395-1399. This chemokine defines a new C-C chemokine family. Evenmore recently, another chemokine exhibiting a CX3C motif has beenidentified, which establishes a fourth structural class.

The present invention provides additional chemokine reagents, e.g.,nucleic acids, proteins and peptides, antibodies, etc., related to thenewly discovered respective chemokines designated TECK; MIP-3α, andMIP-3β.

In other embodiments, the invention provides two genes encoding novel7-transmembrane (7-TM) receptors, presumably G-protein coupled receptorsand likely chemokine receptors. These 7-TM receptors are hypothesized tobe chemokine receptors and have been designated DC CR and M/DC CR. Theirligands have not yet specifically been completely identified. However,the receptors exhibit structural features typical of known chemokinereceptors, e.g., 7 transmembrane spanning structures. They may exhibitproperties of binding many different cytokines at varying specificities(shared or promiscuous binding specificity) or may exhibit high affinityfor one (specific) or a subset (shared) of chemokines.

The described chemokines and receptors should be important for mediatingvarious aspects of cellular, organ, tissue, or organismal physiology ordevelopment.

II. Purified Chemokines, Receptors

Mouse and human Thymus Expressed ChemoKine (TECK) nucleotide and aminoacid sequences are shown in Table 1. Nucleotide and amino acid sequencesof another novel chemokine, from human, designated MIP-3α are providedin Table 2. Nucleotide and derived amino acid sequences of a third novelchemokine, from human, designated MIP-3β are shown in Table 3. Genericdescriptions of physical properties of polypeptides, nucleic acids, andantibodies where directed to one embodiment clearly are generallyapplicable to other chemokines or receptors described herein.

The nucleotide and amino acid sequences of a novel chemokine receptorfound on dendritic cells (DC), from human, and designated DC CR, areprovided in Table 4. The nucleotide and amino acid sequences of anothernovel chemokine receptor found on macrophages and dendritic cells, fromhuman, and designated M/DC CR, are provided in Table 5.

These amino acid sequences, provided amino to carboxy, are important inproviding sequence information on the chemokine ligand or receptor,allowing for distinguishing the protein from other proteins. Moreover,the sequences allow preparation of peptides to generate antibodies torecognize and distinguish such segments, and allow preparation ofoligonucleotide probes, both of which are strategies for isolation,e.g., cloning, of genes encoding such sequences, or related sequences,e.g., natural polymorphic or other variants. Similarities of thechemokines have been observed with other cytokines. See, e.g.,Bosenberg, et al. (1992) Cell 71:1157-1165; Huang, et. al. (1992)Molecular Biology of the Cell 3:349-362; and Pandiella, et al. (1992) J.Biol. Chem. 267:24028-24033. Likewise for the receptors.

TABLE 1 Nucleotide sequence (5′ to 3′) of TECK from mouse and thecorresponding amino acid sequence (amino to carboxy). Signal sequenceProbably runs as shown between Ala and Gln, see SEQ ID NO: 1 and 2.Human sequences are SEQ ID NO: 3 and 4.    1AGGCTACAAGCAGGCACCAGCTCTCAGGACCAGAAAGGCATTGGTGGCCCCCTTAAACCT 60   61TCAGGTATCTGGAGAGGAGATCTAACCTTCACTATGAAACTGTGGCTTTTTGCCTGCCTG 120    1                                 MetLysLeuTrpLeuPheAlaCysLeu 9  121GTTGCCTGTTTTGTTGGGGCCTGGATGCCGGTTGTCCATGCCCAAGGTGCCTTTGAAGAC 180   10ValAlaCysPheValGlyAlaTrpMetProValValHisAlaGlnGlyAlaPheGluAsp 29  181TGCTGCCTGGGTTACCAGCACAGGATCAAATGGAATGTTCTCCGGCATGCTAGGAATTAT 240   30CysCysLeuGlyTyrGlnHisArgIleLysTrpAsnValLeuArgHisAlaArgAsnTyr 49  241CACCAGCAGGAAGTGAGTGGAAGCTGCAACCTACGTGCTGTGAGATTCTACTTCCGCCAG 300   50HisGlnGlnGluValSerGlySerCysAsnLeuArgAlaValArgPheTyrPheArgGln 69  301AAAGTAGTGTGTGGGAATCCAGAGGACATGAATGTGAAGAGGGCGATAAGAATCTTGACA 360   70LysValValCysGlyAsnProGluAspMetAsnValLysArgAlaIleArgIleLeuThr 89  361GCTAGGAAAAGGCTAGTCCACTGGAAGAGCGCCTCAGACTCTCAGACTCAAAGGAAGAAG 420   90AlaArgLysArgLeuValHisTrpLysSerAlaSerAspSerGlnThrGluArgLysLys 109  421TCAAACCATATGAAGTCCAAGGTGGAGAACCCCAACAGTACAAGCGTGAGGAGTGCCACC 480  110SerAsnHisMetLysSerLysValGluAsnProAsnSerThrSerValArgSerAlaThr 129  481CTAGGTCATCCCAGGATGGTGATGATGCCCAGAAAGACCAACAATTAAGTTAATTACTCA 540  130LeuGlyHisProArgMetValMetMetProArgLysThrAsnAsnEnd 144  541GAGTAAGCACCAGCTGGAGGATGGGCGGAGTCTGCTGAAGTGCTGTCTTCTAGGCATGCC 600  601AGTGCCAATGAACTCACTGAAGCTACAGTTTCCTGTACAAGACCAGACCCACCAACGTCT 660  661CAGCATGTACGAGGAAGGAACTACTGCGCTAAAGGCCCTCCCACTCACCAAGGAGCTATT 720  721GGCTATTGATGATTGCTGAGGGAAGGGAGTAATTTTTTTTCTCTTTCTGAAGTGTGACTT 780  781GAGTAAATTGCCCATAGTTCAGTATATAATCCCCAACCTGTGCTCAGGCAAGCAACCCTA 840  841ATTAAATGCAATAGCCACATACAAAAGAAGAGGATATGAATAGTTTGGTAGGAGGGGCTT 900  901GTTAGGAAGAAGACATTAACAGGAGAGAGAGGAGCGAGAGGATAGTGAGTGTGTGAGAGT 960  961GCCTGCACGTGTGAAATGGTCAAAGAATTAAAAAATAAAAACTTAAAAAGCTATTAAAAA 1020 1021GTAAAAAAAATAAA 1034 human Teck cDNA (see SEQ ID NO: 3); signal sequencecleavage is Probably between about Thr and Gln. Hu TECK Protein sequence(see SEQ ID NO: 4). TCGACCCACG CGTCCGCTTG GCCTACAGCC CGGCGGGCATCAGCTCCCTT GACCCAGTGG 60 ATATCGGTGG CCCCGTTATT CGTCCAGGTG CCCAGGGAGGAGGACCCGCC TGCAGC 116 ATG AAC CTG TGG CTC CTG GCC TGC CTG GTG GCC GGCTTC CTG GGA GCC 164 Met Asn Leu Trp Leu Leu Ala Cys Leu Val Ala Gly PheLeu Gly Ala  23         −20                 −15                 −10 TGGGCC CCC GCT GTC CAC ACC CAA GGT GTC TTT GAG GAC TGC TGC CTG 212 Trp AlaPro Ala Val His Thr Gln Gly Val Phe Glu Asp Cys Cys Leu         −5                   1               5 GCC TAC CAC TAC CCC ATTGGG TGG GCT GTG CTC CGG CGC GCC TGG ACT 260 Ala Tyr His Tyr Pro Ile GlyTrp Ala Val Leu Arg Arg Ala Trp Thr 10                  15                  20                  25 TAC CGGATC CAG GAG GTG AGC GGG AGC TGC AAT CTG CCT GCT GCG ATA 308 Tyr Arg IleGln Glu Val Ser Gly Ser Cys Asn Leu Pro Ala Ala Ile                 30                  35                  40 TTC TAC CTCCCC AAG AGA CAC AGG AAG GTG TGT GGG AAC CCC AAA AGC 356 Phe Tyr Leu ProLys Arg His Arg Lys Val Cys Gly Asn Pro Lys Ser             45                  50                  55 AGG GAG GTG CAGAGA GCC ATG AAG CTC CTG GAT GCT CGA AAT AAG GTT 404 Arg Glu Val Gln ArgAla Met Lys Leu Leu Asp Ala Arg Asn Lys Val         60                  65                  70 TTT GCA AAG CTC CACCAC AAC ATG CAG ACC TTC CAA GCA GGC CCT CAT 452 Phe Ala Lys Leu His HisAsn Met Gln Thr Phe Gln Ala Gly Pro His     75                  80                  85 GCT GTA AAG AAG TTG AGTTCT GGA AAC TCC AAG TTA TCA TCA TCC AAG 500 Ala Val Lys Lys Leu Ser SerGly Asn Ser Lys Leu Ser Ser Ser Lys 90                  95                 100                 105 TTT AGCAAT CCC ATC AGC AGC AGC AAG AGG AAT GTC TCC CTC CTG ATA 548 Phe Ser AsnPro Ile Ser Ser Ser Lys Arg Asn Val Ser Leu Leu Ile                110                 115                 120 TCA GCT AATTCA GGA CTG TGAGCCGGCT CATTTCTGGG CTCCATCGGC 596 Ser Ala Asn Ser Gly Leu            125 ACAGGAGGGG CCGGATCTTT CTCCGATAAA ACCGTCGCCC TACAGACCCAGCTGTCCCCA 656 CGCCTCTGTC TTTTGGGTCA AGTCTTAATC CCTGCACCTG AGTTGGTCCTCCCTCTGCAC 716 CCCCACCACC TCCTGCCCGT CTGGCAACTG GAAAGAAGGA GTTGGCCTGATTTTAACCTT 776 TTGCCGCTCC GGGGAACAGC ACAATCCTGG GCAGCCAGTG GCTCTTGTAGAGAAAACTTA 836 GGATACCTCT CTCACTTTCT GTTTCTTGCC GTCCACCCCG GGCCATGCCAGTGTGTCCTC 896 TGGGTCCCCT CCAAAAATCT GGTCATTCAA GGATCCCCTC CCAAGGCTATGCTTTTCTAT 956 AACTTTTAAA TAAACCTTGG GGGGTGAATG GAATAAAAAA AAAAAAAAAAAAAAAA 1012

TABLE 2 Nucleotide sequence (5′ to 3′) of MIP-3α from human and thecorresponding amino acid sequence (amino to carboxy), see SEQ ID NO: 5and 6 and GenBank Accession U77035. ATG TGC TGT ACC AAG AGT TTG CTC CTGGCT GCT TTG ATG TCA GTG CTG 48 Met Cys Cys Thr Lys Ser Leu Leu Leu AlaAla Leu Met Ser Val Leu -26 -25                 -20                 -15CTA CTC CAC CTC TGC GGC GAA TCA GAA GCA GCA AGC AAC TTT GAC TGC 96 LeuLeu His Leu Cys Gly Glu Ser Glu Ala Ala Ser Asn Phe Asp Cys-10                  -5                   1               5 TGT CTT GGATAC ACA GAC CGT ATT CTT CAT CCT AAA TTT ATT GTG GGC 144 Cys Leu Gly TyrThr Asp Arg Ile Leu His Pro Lys Phe Ile Val Gly             10                  15                  20 TTC ACA CGG CAGCTG GCC AAT GAA GGC TGT GAC ATC AAT GCT ATC ATC 192 Phe Thr Arg Gln LeuAla Asn Glu Gly Cys Asp Ile Asn Ala Ile Ile         25                  30                  35 TTT CAC ACA AAG AAAAAG TTG TCT GTG TGC GCA AAT CCA AAA CAG ACT 240 Phe His Thr Lys Lys LysLeu Ser Val Cys Ala Asn Pro Lys Gln Thr     40                  45                  50 TGG GTG AAA TAT ATT GTGCGT CTC CTC AGT AAA AAA GTC AAG AAC ATG 288 Trp Val Lys Tyr Ile Val ArgLeu Leu Ser Lys Lys Val Lys Asn Met 55                  60                  65                  70TAAAAACTGT GGCTTTTCTG GAATGGAATT GGACATAGCC CAAGAACAGA AAGAACCTTG 348CTGGGGTTGG AGGTTTCACT TGCACATCAT GGAGGGTTTA GTGCTTATCT AATTTGTGCC 408TCACTGGACT TGTCCAATTA ATGAAGTTGA TTCATATTGC ATCATAGTTT GCTTTGTTTA 468AGCATCACAT TAAAGTTAAA CTGTATTTTA TGTTATTTAT AGCTGTAGGT TTTCTGTGTT 528TACGTATTTA ATACTAATTT TCCATAAGCT ATTTTGGTTT AGTGCAAAGT ATAAAATTAT 588ATTTGGGGGG GAATAAGATT ATATGGACTT TTTTGCAAGC AACAAGCTAT TTTTTAAAAA 648AAACTATTTA ACATTCTTTT GTTTATATTG TTTTGTCTCC TAAATTGTTG TAATTGCATT 708ATAAAATAAG AAAAATATTA ATAAGACAAA TATTGAAAAT AAAGAAACAA AAAGTTAAAA 768AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAA 801

TABLE 3 Nucleotide sequence (5′ to 3′) of MIP-3β from human and thecorresponding amino acid sequence (amino to carboxy), see SEQ ID NO: 7and 8, and GenBank Accession U77180. Signal sequence cleavage is aboutbetween Ser and Gly.   1GGCACGAGCGGCACGAGCATCACTCACACCTTGCATTTCACCCCTGCATCCCAGTCGCCC 60  61TGCAGCCTCACACAGATCCTGCACACACCCAGACAGCTGGCGCTCACACATTCACCGTTG 120 121GCCTGCCTCTGTTCACCCTCCATGGCCCTGCTACTGGCCCTCAGCCTGCTGGTTCTCTGG 180   1                     MetAlaLeuLeuLeuAlaLeuSerLeuLeuValLeuTrp 13 181ACTTCCCCAGCCCCAACTCTGAGTGGCACCAATGATGCTGAAGACTGCTGCCTGTCTGTG 240  14ThrSerProAlaProThrLeuSerolyThrAsnAspAlaGluAspCysCysLeuSerVal 33 241ACCCAGAAACCCATCCCTGGGTACATCGTGAGGAACTTCCACTACCTTCTCATCAAGGAT 300  34ThrGlnLysProIleProGlyTyrIleValArgAsnPheHisTyrLeuLeuIleLysAsp 53 301GGCTGCAGGGTGCCTGCTGTAGTGTTCACCACACTGAGGGGCCGCCAGCTCTGTGCACCC 360  54GlyCysArgValProAlaValValPheThrThrLeuArgGlyArgGlnLeuCysAlaPro 73 361CCAGACCAGCCCTGGGTAGAACGCATCATCCAGAGACTGCAGAGGACCTCAGCCAAGATG 420  74ProAspGlnProTrpValGluArgIleIleGlnArgLeuGlnArgThrSerAlaLysMet 93 421AAGCGCCGCAGCAGTTAACCTATCACCGTGCAGAGGGAGCCCGGACTCCGAGTCAAGCAT 480  94LysArgArgSerSerEnd 98 481TGTGAATTATTACCTAACCTGGGGAACCGAGGACCAGAAGGAAGGACCAGGCTTCCAGCT 540 541CCTCTGCACCAGACCTGACCAGCCAGGACAGCGCCTCGGGTGTGTCTGAGTGTGAGTGTG 600 601AGCGAGAGGGTGAGTGTGGTCTAGAGTAAAGCTCCTCCACCCCCAGATTGCAATGCTACC 660 661AATAAAGCCGCCTGGTGTTTACAACTAAAAAAAAAAAAA 699

TABLE 4 Nucleotide sequence (5′ to 3′) of chemokine receptor, DC CR,from human and the corresponding amino acid sequence (amino to carboxy),see SEQ ID NO: 9 and 10. Nucleotide 579 may be A, C, G, or T, and thecodon may code for His or Gln.    1ATGTTTTCGACTCCAGTGAAGATTATTTTGTGTCAGTCAATACTTCATATTACTCAGTTG 60    1MetPheSerThrProValLysIleIleLeuCysGlnSerIleLeuHisIleThrGlnLeu 20   61ATTCTGAGATGTTACTGTGCTCCTTGCAGGAGGTCAGGCAGTTCTCCAGGCTATTTGTAC 120   21IleLeuArgCysTyrCysAlaProCysArgArgSerGlySerSerProGlyTyrLeuTyr 40  121CGAATTGCCTACTCCTTGATCTGTGTTCTTGGCCTCCTGGGGAATATTCTGGTGGTGATC 180   41ArgIleAlaTyrSerLeuIleCysValLeuGlyLeuLeuGlyAsnIleLeuValValIle 60  181ACCTTTGCTTTTTATAAGAAGGCCAGGTCTATGACAGACGTCTATCTCTTGAACATGGCC 240   61ThrPheAlaPheTyrLysLysAlaArgSerMetThrAspValTyrLeuLeuAsnMetAla 80  241ATTGCAGACATCCTCTTTGTTCTTACTCTCCCATTCTGGGCAGTGAGTCATGCCACTGGT 300   81IleAlaAspIleLeuPheValLeuThrLeuProPheTrpAlaValSerHisAlaThrGly 100  301GCGTGGGTTTTCAGCAATGCCACGTGCAAGTTGCTAAAAGGCATCTATGCCATCAACTTT 360  101AlaTrpValPheSerAsnAlaThrCysLysLeuLeuLysGlyIleTyrAlaIleAsnPhe 120  361AACTGCGGGATGCTGCTCCTGACTTGCATTAgCATGGACCGGTACATCGCCATTGTACAG 420  121AsnCysGlyMetLeuLeuLeuThrCysIleSerMetAspArgTyrIleAlaIleValGln 140  421GCGACTAAGTCATTCCGGCTCCGATCCAGAACACTACCGCGCAGCAAAATCATCTGCCTT 480  141AlaThrLysSerPheArgLeuArgSerArgThrLeuProArgSerLysIleIleCysLeu 160  481GTTGTGTGGGGGCTGTCAGTCATCATCTCCAGCTCAACTTTTGTCTTCAACCAAAAATAC 540  161ValValTrpGlyLeuSerValIleIleSerSerSerThrPheValPheAsnGlnLysTyr 180  541AACACCCAAGGCAGCGATGTCTGTGAACCCAAGTACCAAACTGTCTCGGAGCCCATCAGG 600  181AsnThrGlnGlySerAspValCysGluProLysTyrGlnThrValSerGluProIleArg 200  601TGGAAGCTGCTGATGTTGGGGCTTGAGCTACTCTTTGGTTTCTTTATCCCTTTGATGTTC 660  201TrpLysLeuLeuMetLeuGlyLeuGluLeuLeuPheGlyPhePheIleProLeuMetPhe 220  661ATGATATTTTGTTACACGTTCATTGTCAAAACCTTGGTGCAAGCTCAGAATTCTAAAAGG 720  221MetIlePheCysTyrThrPheIleValLysThrLeuValGlnAlaGlnAsnSerLysArg 240  721CACAAAGCCATCCGTGTAATCATAGCTGTGGTGCTTGTGTTTCTGGCTTGTCAGATTCCT 780  241HisLysAlaIleArgValIleIleAlaValValLeuValPheLeuAlaCysGlnIlePro 260  781CATAACATGGTCCTGCTTGTGACGGCTGCTAATTTGGGTAAAATGAACCGATCCTGCCAG 840  261HisAsnMetValLeuLeuValThrAlaAlaAsnLeuGlyLysMetAsnArgSerCysGln 280  841AGCGAAAAGCTAATTGGCTATACGAAAACTGTCACAGAAGTCCTGGCTTTCCTGCACTGC 900  281SerGluLysLeuIleGlyTyrThrLysThrValThrGluValLeuAlaPheLeuHisCys 300  901TGCCTGAACCCTGTGCTCTACGCTTTTATTGGGCAGAAGTTCAGAAACTACTTTCTGAAG 960  301CysLeuAsnProValLeuTyrAlaPheIleGlyGlnLysPheArgAsnTyrPheLeuLys 320  961ATCTTGAAGGACCTGTGGTGTGTGAGAAGGAAGTACAAGTCCTCAGGCTTCTCCTGTGCC 1020  321IleLeuLysAspLeuTrpCysValArgArgLysTyrLysSerSerGlyPheSerCysAla 340 1021GGGAGGTACTCAGAAAACATTTCTCGGCAGACCAGTGAGACCGCAGATAACGACAATGCG 1080  341GlyArgTyrSerGluAsnIleSerArgGlnThrSerGluThrAlaAspAsnAspAsnAla 360 1081TCGTCCTTCACTATGTGATAGAAAGCTGAGTCTCCCTAA 1119  361 SerSerPheThrMetEnd 365

TABLE 5 Nucleotide sequence (5′ to 3′) of chemokine receptor, M/DC CR,from human and the corresponding amino acid sequence (amino to carboxy),see SEQ ID NO: 11 and 12.    1GAGGAAGCTCCTTCGGGGGGTGAGCAAACTTTTTAAAATGCAGAAATTATGATCTACACC 60                                                MetIleTyrThr 4   61CGTTTCTTAAAAGGCAGTCTGAAGATGGCCAATTACACGCTGGCACCAGAGGATGAATAT 120    5ArgPheLeuLysGlySerLeuLysMetAlaAsnTyrThrLeuAlaProGluAspGluTyr 24  121GATGTCCTCATAGAAGGTGAACTGGAGAGCGATGAGGCAGAGCAATGTGACAAGTATGAC 180   25AspValLeuIleGluGlyGluLeuGluSerAspGluAlaGluGlnCysAspLysTyrAsp 44  181GCCCAGGCACTCTCAGCCCAGCTGGTGCCATCACTCTGCTCTGCTGTGTTTGTGATCGGT 240   45AlaGlnAlaLeuSerAlaGlnLeuValProSerLeuCysSerAlaValPheValIleGly 64  241GTCCTGGACAATCTCCTGGTTGTGCTTATCCTGGTAAAATATAAAGGACTCAAACGCGTG 300   65ValLeuAspAsnLeuLeuValValLeuIleLeuValLysTyrLysGlyLeuLysArgVal 84  301GAAAATATCTATCTTCTAAACTTGGCAGTTTCTAACTTGTGTTTCTTGCTTACCCTGCCC 360   85GluAsnIleTyrLeuLeuAsnLeuAlaValSerAsnLeuCysPheLeuLeuThrLeuPro 104  361TTCTGGGCTCATGCTGGGGGCGATCCCATGTGTAAAATTCTCATTGGACTGTACTTCGTG 420  105PheTrpAlaHisAlaGlyGlyAspProMetCysLysIleLeuIleGlyLeuTyrPheVal 124  421GGCCTGTACAGTGAGACATTTTTCAATTGCCTTCTGACTGTGCAAAGGTACCTAGTGTTT 480  125GlyLeuTyrSerGluThrPhePheAsnCysLeuLeuThrValGlnArgTyrLeuValPhe 144  481TTGCACAAGGGCAACTTTTTCTCAGCCAGGAGGAGGGTGCCCTGTGGCATCATTACAAGT 540  145LeuHisLysGlyAsnPhePheSerAlaArgArgArgValProCysGlyIleIleThrSer 164  541GTCCTGGCATGGGTAACAGCCATTCTGGCCACTTTGCCTGAATTCGTGGTTTATAAACCT 600  165ValLeuAlaTrpValThrAlaIleLeuAlaThrLeuProGluPheValValTyrLysPro 184  601CAGATGGAAGACCAGAAATACAAGTGTGCATTTAGCAGAACTCCCTTCCTGCCAGCTGAT 660  185GlnMetGluAspGlnLysTyrLysCysAlaPheSerArgThrProPheLeuProAlaAsp 204  661GAGACATTCTGGAAGCATTTTCTGACTTTAAAAATGAACATTTCGGTTCTTGTCCTCCCC 720  205GluThrPheTrpLysHisPheLeuThrLeuLysMetAsnIleSerValLeuValLeuPro 224  721CTATTTATTTTTACATTTCTCTATGTGCAAATGAGAAAAACACTAAGGTTCAGGGAGCAG 780  225LeuPheIlePheThrPheLeuTyrValGlnMetArgLysThrLeuArgPheArgGluGln 244  781AGGTATAGCCTTTTCAAGCTTGTTTTTGCCGTAATGGTAGTCTTCCTTCTGATGTGGGCG 840  245ArgTyrSerLeuPheLysLeuValPheAlaValMetValValPheLeuLeuMetTrpAla 264  841CCCTACAATATTGCATTTTTCCTGTCCACTTTCAAAGAACACTTCTCCCTGAGTGACTGC 900  265ProTyrAsnIleAlaPhePheLeuSerThrPheLysGluHisPheSerLeuSerAspCys 284  901AAGAGCAGCTACAATCTGGACAAAAGTGTTCACATCACTAAACTCATCGCCACCACCCAC 960  285LysSerSerTyrAsnLeuAspLysSerValHisIleThrLysLeuIleAlaThrThrHis 304  961TGCTGCATCAACCCTCTCCTGTATGCGTTTCTTGATGGGACATTTAGCAAATACCTCTGC 1020  305CysCysIleAsnProLeuLeuTyrAlaPheLeuAspGlyThrPheSerLysTyrLeuCys 324 1021CGCTGTTTCCATCTGCGTAGTAACACCCCACTTCAACCCAGGGGGCAGTCTGCACAAGGC 1080  325ArgCysPheHisLeuArgSerAsnThrProLeuGlnProArgGlyGlnSerAlaGlnGly 344 1081ACATCGAGGGAAGAACCTGACCATTCCACCCAAGTGTAAACTAGCATCCACCAAATGCAA 1140  345ThrSerArgGluGluProAspHisSerThrGluValEnd 356 1141GAAGAATAAACATGGATTTTCATCTTTCTGCATTATTTCATGTAAATTTTCTACACATTT 1200 1201GTATACAAAATCGGATACAGGAAGAAAAGGGAGAGGTGAGCTAACATTTGCTAAGCACTG 1260 1261AATTTGTCTCAGGCACCGTGCAAGGCTCTTTACAAACGTGAGCTCCTTCGCCTCCTACCA 1320 1321CTTGTCCATAGTGTGGATAGGACTAGTCTCATTTCTCTGAGAAGAAAACTAAGGCGCGGA 1380 1381AATTTGTCTAAGATCACATAACTAGGAAGTGGCAGAACTGATTCTCCAGCCCTGGTAGCA 1440 1441TTTGCTCAGAGCCTACGCTTGGTCCAGAACATCAAACTCCAAACCCTGGGGACAAACGAC 1500 1501ATGAAATAAATGTATTTTAAAACATATAAAAAAAAAAAAAAAAAAAA 1547

TABLE 6 Alignment of M/DC CR with CKR-1 through CKR-4. The otherchemokine receptors are SEQ ID NO: 13-17. An asterisk indicates fullyconserved residue among all five receptors; a period representsconservative substitutions among all five receptors. M/DC CRMIYTRFLKGSLKMANYTLAPEDEYDVLIEGELESDEAEQCDKYDAQALS C-C CKR-1                METPNTTEDYDTTTEFDYGDATPCQKVNERAFG C-C CKR-2        MLSTSRSRFIRNTNESGEEVTTFFDYDYGAPCHKFDVKQIG C-C CKR-3                MTTSLDTVETFGTTSYYDDVGLLCEKADTRALM C-C CKR-4           MNPTDIADTTLDESIYSNYYLYESIPKPCTKEGIKAFG                                       * *   . . M/DC CRAQLVPSLCSAVFVIGVLDNLLVVLILVKYKGLKRVENIYLLNLAVSNLCF C-C CKR-1AQLLPPLYSLVFVIGLVGNILVVLVLVQYKRLKNMTSIYLLNLAISDLLF C-C CKR-2AQLLPPLYSLVFIFGFVGNMLVVLILINCKKLKCLTDIYLLNLAISDLLF C-C CKR-3AQFVPPLYSLVFTVGLLGNVVVVMILIKYRRLRIMTNIYLLNLAISDLLF C-C CKR-4ELFLPPLYSLVFVFGLLGNSVVVLVLFKYKRLRSMTDVYLLNLAISDLLF   ..*.* * **  * ..*.**..* . . *. .  .******.*.* * M/DC CRLLTLPFWAHAG-------GDPMCKILIGLYFVGLYSETFFNCLLTVQRYL C-C CKR-1LFTLPFWIDYKLKDDWVFCDAMCKILSGFYYTGLYSEIFFIILLTIDRYL C-C CKR-2LITLPLWAH-SAANEWVFGNAMCKLFTGLYHIGYFGGIFFIILLTIDRYL C-C CKR-3LVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSEIFFIILLTIDRYL C-C CKR-4VFSLPFWGYYA-ADQWVFGLGLCKMISWMYLVGFYSGIFFVMLMSIDRYL ..**.*           *  .**..   *  * ..  **  *....*** M/DC CRVFLHKGNFFSAR-RRVPCGIITSVLAWVTAILATLPEFVVYKPQMEDQKY C-C CKR-1AIVH--AVFALRARTVTFGVITSIIIWALAILASMPGLYFSKTQWEFTHH C-C CKR-2AIVH--AVFALKARTVTFGVVTSVITWLVAVFASVPGIIFTKCQKEDSVY C-C CKR-3AIVH--AVFALRARTVTFGVTTSIVTWGLAVLAALPEFIFYETEELFEET C-C CKR-4AIVH--AVFSLRARTLTYGVITSLATWSVAVFASLPGFLFSTCYTERNHT  ..*    *. . *.  *..**.  *  *..*..* . M/DC CRKCAFSRTPFLPADETF-WKHFLTLKMNISVLVLPLFIFTFLYVQMRKTL- C-C CKR-1TCS----LHFPHESLREWKLFQALKLNLFGLVLPLLVMIICYTGIIKILL C-C CKR-2VCG----PYFPR----GWNNFHTIMRNILGLVLPLLIMVICYSGILKTLL C-C CKR-3LCS----ALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLL C-C CKR-4YCK----TKYSLNST-TWKVLSSLEINILGLVIPLGIMLFCYSMIIRTLQ  *        .      *  ...   .  **.** .  . *  . . * M/DC CR--RFREQRYSLFKLVFAVMVVFLLMWAPYNIAFFLSTFKEHFSLSDCKSS C-C CKR-1RRPNEKK-SKAVRLIFVIMIIFFLFWTPYNLTILISVFQDFLFTHECEQS C-C CKR-2RCRNEKKRHRAVRVIFTIMIVYFLFWTPYNIVILLNTFQEFFGLSNCEST C-C CKR-3RCPSKKK-YKAIRLIFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERS C-C CKR-4HCKNEKK-NKAVKMIFAVVVLFLGFWTPYNIVLFLETLVELEVLQDCTFE       .     ...* .....  *.***. ...          .* M/DC CRYNLDKSVHITKLIATTHCCINPLLYAFLDGTFSKYLCRCFH--------- C-C CKR-1RHLDLAVQVTEVIAYTHCCVNPVIYAFVGERFRKYLRQLFH-RRVA---- C-C CKR-2SQLDQATQVTETLGMTHCCINPIIYAFVGEKFRSLFHIALG-CRIAPLQK C-C CKR-3KHLDLVMLVTEVIAYSHCCMNPVIYAFVGERFRKYLRHFFH-RHLL---- C-C CKR-4RYLDYAIQATETLAFVHCCLNPIIYFFLGEKFRKYILQLFKTCRGLFVLC  **     *  ..  ***.**..* *..  *   .   . M/DC CR---------------LRSNTPLQPRGQSAQGTSREEP--DHSTEV* C-C CKR-1-------VHLVKWLPFLSVDRLERVSSTSPSTGEHELSA----GF* C-C CKR-2PVCGGPGVRPGKNVKVTTQGLLDGRGKGKSIGRAPEASLQDKEGA* C-C CKR-3-------MHLGRYIPFLPSEKLERTSSVSPSTAEPELSI----VF* C-C CKR-4QYCG--------LLQIYSAD------TPSSSYTQSTMDHDLHDAL*

As used herein, the term “TECK” shall encompass, when used in a proteincontext, a protein having mature mouse or human amino acid sequences, asshown in Table 1. The invention also embraces a polypeptide comprising asignificant fragment of such protein. It also refers to a polypeptidewhich is a species counterpart, e.g., which exhibits similar biologicalfunction, and is more homologous in natural encoding sequence than othergenes from that species. Typically, such chemokine will also interactwith its specific binding components, e.g., receptor. These bindingcomponents, e.g., antibodies, typically bind to the chemokine with highaffinity, e.g., at least about 100 nM, usually better than about 30 nM,preferably better than about 10 nM, and more preferably at better thanabout 3 nM. Homologous proteins would be found in mammalian speciesother than mouse, e.g., rats, dogs, cats, and primates. Non-mammalianspecies should also possess structurally or functionally related genesand proteins.

The term “polypeptide” as used herein includes a significant fragment orsegment, and encompasses a stretch of amino acid residues of at leastabout 8 amino acids, generally at least 10 amino acids, more generallyat least 12 amino acids, often at least 14 amino acids, more often atleast 16 amino acids, typically at least 18 amino acids, more typicallyat least 20 amino acids, usually at least 22 amino acids, more usuallyat least 24 amino acids, preferably at least 26 amino acids, morepreferably at least 28 amino acids, and, in particularly preferredembodiments, at least about 30 or more amino acids, e.g., about 35, 40,45, 50, 60, 75, 80, 100, 120, etc. Similar proteins will likely comprisea plurality of such segments. Such fragments may have ends which beginand/or end at virtually all positions, e.g., beginning at residues 1, 2,3, etc., and ending at, e.g., 69, 68, 67, 66, etc., in all combinations.Particularly interesting peptides have ends corresponding to structuraldomain boundaries. See, e.g., PHD and DSC programs, Rost and Sander(1994) Proteins 19:55-72; and King and Sternberg (1996) Protein Science5:2298-2310.

The term “binding composition” refers to molecules that bind withspecificity to the respective chemokine or receptor, e.g., in aligand-receptor type fashion or an antibody-antigen interaction. Thesecompositions may be compounds, e.g., proteins, which specificallyassociate with the chemokine or receptor, including naturalphysiologically relevant protein-protein interactions, either covalentor non-covalent. The binding composition may be a polymer, or anotherchemical reagent. No implication as to whether the chemokine presents aconcave or convex shape in its ligand-receptor interaction isrepresented, other than the interaction exhibit similar specificity,e.g., specific affinity. A functional analog may be a ligand withstructural modifications, or may be a wholly unrelated molecule, e.g.,which has a molecular shape which interacts with the appropriate ligandbinding determinants. The ligands may serve as agonists or antagonistsof the receptor, see, e.g., Goodman, et al. (eds.) (1990) Goodman &Gilman's: The Pharmacological Bases of Therapeutics (8th ed.), PergamonPress.

Substantially pure means that the protein is free from othercontaminating proteins, nucleic acids, and/or other biologicalstypically derived from the original source organism. Purity may beassayed by standard methods, and will ordinarily be at least about 40%pure, more ordinarily at least about 50% pure, generally at least about60% pure, more generally at least about 70% pure, often at least about75% pure, more often at least about 80% pure, typically at least about85% pure, more typically at least about 90% pure, preferably at leastabout 95% pure, more preferably at least about 98% pure, and in mostpreferred embodiments, at least 99% pure. Analyses will typically be byweight, but may be by molar amounts.

Solubility of a polypeptide or fragment depends upon the environment andthe polypeptide. Many parameters affect polypeptide solubility,including temperature, electrolyte environment, size and molecularcharacteristics of the polypeptide, and nature of the solvent.Typically, the temperature at which the polypeptide is used ranges fromabout 4° C. to about 65° C. Usually the temperature at use is greaterthan about 18° C. and more usually greater than about 22° C. Fordiagnostic purposes, the temperature will usually be about roomtemperature or warmer, but less than the denaturation temperature ofcomponents in the assay. For therapeutic purposes, the temperature willusually be body temperature, typically about 37° C. for humans, thoughunder certain situations the temperature may be raised or lowered insitu or in vitro.

The electrolytes will usually approximate in situ physiologicalconditions, but may be modified to higher or lower ionic strength whereadvantageous. The actual ions may be modified, e.g., to conform tostandard buffers used in physiological or analytical contexts.

The size and structure of the polypeptide should generally be in asubstantially stable state, and usually not in a denatured state. Thepolypeptide may be associated with other polypeptides in a quaternarystructure, e.g., to confer solubility, or associated with lipids ordetergents in a manner which approximates natural lipid bilayerinteractions.

The solvent will usually be a biologically compatible buffer, of a typeused for preservation of biological activities, and will usuallyapproximate a physiological solvent. Usually the solvent will have aneutral pH, typically between about 5 and 10, and preferably about 7.5.On some occasions, a detergent will be added, typically a mildnon-denaturing one, e.g., CHS or CHAPS, or a low enough concentration asto avoid significant disruption of structural or physiologicalproperties of the protein.

Solubility is reflected by sedimentation measured in Svedberg units,which are a measure of the sedimentation velocity of a molecule underparticular conditions. The determination of the sedimentation velocitywas classically performed in an analytical ultracentrifuge, but istypically now performed in a standard ultracentrifuge. See, Freifelder(1982) Physical Biochemistry (2d ed.), W.H. Freeman; and Cantor andSchimmel (1980) Biophysical Chemistry, parts 1-3, W.H. Freeman & Co.,San Francisco. As a crude determination, a sample containing aputatively soluble polypeptide is spun in a standard full sizedultracentrifuge at about 50K rpm for about 10 minutes, and solublemolecules will remain in the supernatant. A soluble particle orpolypeptide will typically be less than about 30 S, more typically lessthan about 15 S, usually less than about 10 S, more usually less thanabout 6 S, and, in particular embodiments, preferably less than about 4S, and more preferably less than about 3 S.

III. Physical Variants

This invention also encompasses proteins or peptides having substantialamino acid sequence homology with the amino acid sequence of eachrespective chemokine or receptor. The variants include species orpolymorphic variants.

Amino acid sequence homology, or sequence identity, is determined byoptimizing residue matches, if necessary, by introducing gaps asrequired. This changes when considering conservative substitutions asmatches. Conservative substitutions typically include substitutionswithin the following groups: glycine, alanine; valine, isoleucine,leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine,threonine; lysine, arginine; and phenylalanine, tyrosine. Homologousamino acid sequences are typically intended to include natural allelicand interspecies variations in each respective protein sequence. Typicalhomologous proteins or peptides will have from 25-100% homology (if gapscan be introduced), to 50-100% homology (if conservative substitutionsare included) with the amino acid sequence of the appropriate chemokineor receptor. Homology measures will be at least about 35%, generally atleast 40%, more generally at least 45%, often at least 50%, more oftenat least 55%, typically at least 60%, more typically at least 65%,usually at least 70%, more usually at least 75%, preferably at least80%, and more preferably at least 80%, and in particularly preferredembodiments, at least 85% or more. See also Needleham, et al. (1970) J.Mol. Biol. 48:443-453; Sankoff, et al. (1983) Chapter One in Time Warps,String Edits, and Macromolecules: The Theory and Practice of SequenceComparison Addison-Wesley, Reading, Mass.; and software packages fromIntelliGenetics, Mountain View, Calif.; and the University of WisconsinGenetics Computer Group, Madison, Wis.

Each of the isolated chemokine or receptor DNAs can be readily modifiedby nucleotide substitutions, nucleotide deletions, nucleotideinsertions, and inversions of nucleotide stretches. These modificationsresult in novel DNA sequences which encode these antigens, theirderivatives, or proteins having similar physiological, immunogenic, orantigenic activity. These modified sequences can be used to producemutant antigens or to enhance expression. Enhanced expression mayinvolve gene amplification, increased transcription, increasedtranslation, and other mechanisms. Such mutant chemokine or receptorderivatives include predetermined or site-specific mutations of therespective protein or its fragments. “Mutant chemokine” encompasses apolypeptide otherwise falling within the homology definition of thechemokine as set forth above, but having an amino acid sequence whichdiffers from that of the chemokine as found in nature, whether by way ofdeletion, substitution, or insertion. These include substitution levelsfrom none, one, two, three, etc. In particular, “site specific mutantchemokine” generally includes proteins having significant homology witha ligand having sequences of Table 1 through 3, and as sharing variousbiological activities, e.g., antigenic or immunogenic, with thosesequences, and in preferred embodiments contain most of the disclosedsequences. Similar concepts apply to the different chemokine proteinembodiments, particularly those found in various warm blooded animals,e.g., mammals and birds. As stated before, it is emphasized thatdescriptions are generally meant to encompass the various chemokineproteins, not limited to the mouse or human embodiments specificallydiscussed. Similar concepts apply to the receptor embodiments.

Although site specific mutation sites are often predetermined, mutantsneed not be site specific. Chemokine mutagenesis can be conducted bymaking amino acid insertions or deletions. Substitutions, deletions,insertions, or combinations may be generated to arrive at a finalconstruct. Insertions include amino- or carboxy-terminal fusions. Randommutagenesis can be conducted at a target codon and the expressed mutantscan then be screened for the desired activity. Methods for makingsubstitution mutations at predetermined sites in DNA having a knownsequence are well known in the art, e.g., by M13 primer mutagenesis orpolymerase chain reaction (PCR) techniques. See also Sambrook, et al.(1989) and Ausubel, et al. (1987 and Supplements).

The mutations in the DNA normally should not place coding sequences outof reading frames and preferably will not create complementary regionsthat could hybridize to produce secondary mRNA structure such as loopsor hairpins.

The present invention also provides recombinant proteins, e.g.,heterologous fusion proteins using segments from these proteins. Aheterologous fusion protein is a fusion of proteins or segments whichare naturally not normally fused in the same manner. Thus, the fusionproduct of an immunoglobulin with a chemokine or receptor polypeptide isa continuous protein molecule having sequences fused in a typicalpeptide linkage, typically made as a single translation product andexhibiting properties derived from each source peptide. A similarchimeric concept applies to heterologous nucleic acid sequences.

In addition, new constructs may be made from combining similarfunctional domains from other proteins. For example, ligand-binding orother segments may be “swapped” between different new fusionpolypeptides or fragments. See, e.g., Cunningham, et al. (1989) Science243:1330-1336; and O'Dowd, et al. (1988) J. Biol. Chem. 263:15985-15992.Thus, new chimeric polypeptides exhibiting new combinations ofspecificities will result from the functional linkage of ligand-bindingspecificities and other functional domains.

The phosphoramidite method described by Beaucage and Carruthers (1981)Tetra. Letts. 22:1859-1862, will produce suitable synthetic DNAfragments. A double stranded fragment will often be obtained either bysynthesizing the complementary strand and annealing the strand togetherunder appropriate conditions or by adding the complementary strand usingDNA polymerase with an appropriate primer sequence, e.g., PCRtechniques.

IV. Functional Variants

The blocking of physiological response to various embodiments of thesechemokines may result from the inhibition of binding of the ligand toits receptor, likely through competitive inhibition. Thus, in vitroassays of the present invention will often use isolated protein,membranes from cells expressing a recombinant membrane associatedchemokine, soluble fragments comprising receptor binding segments ofthese ligands, or fragments attached to solid phase substrates. Theseassays will also allow for the diagnostic determination of the effectsof either binding segment mutations and modifications, or ligandmutations and modifications, e.g., ligand analogs.

This invention also contemplates the use of competitive drug screeningassays, e.g., where neutralizing antibodies to antigen or receptorfragments compete with a test compound for binding to the protein. Inthis manner, the antibodies can be used to detect the presence ofpolypeptides which share one or more antigenic binding sites of theligand and can also be used to occupy binding sites on the protein thatmight otherwise interact with a receptor.

Additionally, neutralizing antibodies against a specific chemokineembodiment and soluble fragments of the chemokine which contain a highaffinity receptor binding site, can be used to inhibit chemokineactivity in tissues, e.g., tissues experiencing abnormal physiology.

“Derivatives” of chemokine antigens include amino acid sequence mutants,glycosylation variants, and covalent or aggregate conjugates with otherchemical moieties. Covalent derivatives can be prepared by linkage offunctionalities to groups which are found in chemokine amino acid sidechains or at the N- or C-termini, by means which are well known in theart. These derivatives can include, without limitation, aliphatic estersor amides of the carboxyl terminus, or of residues containing carboxylside chains, O-acyl derivatives of hydroxyl group-containing residues,and N-acyl derivatives of the amino terminal amino acid or amino-groupcontaining residues, e.g., lysine or arginine. Acyl groups are selectedfrom the group of alkyl-moieties including C3 to C18 normal alkyl,thereby forming alkanoyl aroyl species. Covalent attachment to carrierproteins may be important when immunogenic moieties are haptens.

In particular, glycosylation alterations are included, e.g., made bymodifying the glycosylation patterns of a polypeptide during itssynthesis and processing, or in further processing steps. Particularlypreferred means for accomplishing this are by exposing the polypeptideto glycosylating enzymes derived from cells which normally provide suchprocessing, e.g., mammalian glycosylation enzymes. Deglycosylationenzymes are also contemplated. Also embraced are versions of the sameprimary amino acid sequence which have other minor modifications,including phosphorylated amino acid residues, e.g., phosphotyrosine,phosphoserine, or phosphothreonine.

A major group of derivatives are covalent conjugates of the respectivechemokine or receptor or fragments thereof with other proteins orpolypeptides. These derivatives can be synthesized in recombinantculture such as N- or C-terminal fusions or by the use of agents knownin the art for their usefulness in cross-linking proteins throughreactive side groups. Preferred chemokine derivatization sites withcross-linking agents are at free amino groups, carbohydrate moieties,and cysteine residues.

Fusion polypeptides between these chemokines and other homologous orheterologous proteins, e.g., other chemokines, are also provided. Manygrowth factors and cytokines are homodimeric entities, and a repeatconstruct may have various advantages, including lessened susceptibilityto proteolytic cleavage. Moreover, many receptors require dimerizationto transduce a signal, and various dimeric ligands or domain repeats canbe desirable. Homologous polypeptides may be fusions between differentsurface markers, resulting in, e.g., a hybrid protein exhibitingreceptor binding specificity. Likewise, heterologous fusions may beconstructed which would exhibit a combination of properties oractivities of the derivative proteins. Typical examples are fusions of areporter polypeptide, e.g., luciferase, with a segment or domain of aligand, e.g., a receptor-binding segment, so that the presence orlocation of the fused ligand may be easily determined. See, e.g., Dull,et al., U.S. Pat. No. 4,859,609. Other gene fusion partners includebacterial β-galactosidase, trpE, Protein A, β-lactamase, alpha amylase,alcohol dehydrogenase, a FLAG fusion, and yeast alpha mating factor.See, e.g., Godowski, et al. (1988) Science 241:812-816.

The phosphoramidite method described by Beaucage and Carruthers (1981)Tetra. Letts. 22:1859-1862, will produce suitable synthetic DNAfragments. A double stranded fragment will often be obtained either bysynthesizing the complementary strand and annealing the strand togetherunder appropriate conditions or by adding the complementary strand usingDNA polymerase with an appropriate primer sequence.

Such polypeptides may also have amino acid residues which have beenchemically modified by phosphorylation, sulfonation, biotinylation, orthe addition or removal of other moieties, particularly those which havemolecular shapes similar to phosphate groups. In some embodiments, themodifications will be useful labeling reagents, or serve as purificationtargets, e.g., affinity tags as FLAG.

Fusion proteins will typically be made by either recombinant nucleicacid methods or by synthetic polypeptide methods. Techniques for nucleicacid manipulation and expression are described generally, for example,in Sambrook, et al. (1989) Molecular Cloning: A Laboratory Manual (2ded.), Vols. 1-3, Cold Spring Harbor Laboratory. Techniques for synthesisof polypeptides are described, for example, in Merrifield (1963) J.Amer. Chem. Soc. 85:2149-2156; Merrifield (1986) Science 232: 341-347;and Atherton, et al. (1989) Solid Phase Peptide Synthesis: A PracticalApproach, IRL Press, Oxford; and chemical ligation, e.g., Dawson, et al.(1994) Science 266:776-779, a method of linking long synthetic peptidesby a peptide bond.

This invention also contemplates the use of derivatives of thesechemokines or receptors other than variations in amino acid sequence orglycosylation. Such derivatives may involve covalent or aggregativeassociation with chemical moieties. These derivatives generally fallinto the three classes: (1) salts, (2) side chain and terminal residuecovalent modifications, and (3) adsorption complexes, for example withcell membranes. Such covalent or aggregative derivatives are useful asimmunogens, as reagents in immunoassays, or in purification methods suchas for affinity purification of ligands or other binding ligands. Forexample, a chemokine antigen can be immobilized by covalent bonding to asolid support such as cyanogen bromide-activated Sepharose, by methodswhich are well known in the art, or adsorbed onto polyolefin surfaces,with or without glutaraldehyde cross-linking, for use in the assay orpurification of anti-chemokine antibodies or its receptor. Thesechemokines can also be labeled with a detectable group, for exampleradioiodinated by the chloramine T procedure, covalently bound to rareearth chelates, or conjugated to a fluorescent moiety for use indiagnostic assays. Purification of chemokine may be effected byimmobilized antibodies or receptor.

Other modifications may be introduced with the goal of modifying thetherapeutic pharmacokinetics or pharmacodynamics of a target chemokine.For example, certain means to minimize the size of the entity mayimprove its pharmacoaccessibility; other means to maximize size mayaffect pharmacodynamics.

A solubilized chemokine or appropriate fragment of this invention can beused as an immunogen for the production of antisera or antibodiesspecific for the ligand or fragments thereof. The purified chemokinescan be used to screen monoclonal antibodies or chemokine-bindingfragments prepared by immunization with various forms of impurepreparations containing the protein. In particular, antibody equivalentsinclude antigen binding fragments of natural antibodies, e.g., Fv, Fab,or F(ab)₂. Purified chemokines can also be used as a reagent to detectantibodies generated in response to the presence of elevated levels ofthe protein or cell fragments containing the protein, both of which maybe diagnostic of an abnormal or specific physiological or diseasecondition. Additionally, chemokine protein fragments, or theirconcatenates, may also serve as immunogens to produce antibodies of thepresent invention, as described immediately below. For example, thisinvention contemplates antibodies raised against amino acid sequencesshown in Tables 1 through 3, or proteins containing them. In particular,this invention contemplates antibodies having binding affinity to orbeing raised against specific fragments, e.g., those which are predictedto lie on the outside surfaces of protein tertiary structure. Similarconcepts apply to antibodies specific for receptors of the invention.

The present invention contemplates the isolation of additional closelyrelated species variants. Southern and Northern blot analysis shouldestablish that similar genetic entities exist in other mammals, andestablish the stringency of hybridization conditions to isolate such. Itis likely that these chemokines and receptors are widespread in speciesvariants, e.g., rodents, lagomorphs, carnivores, artiodactyla,perissodactyla, and primates.

The invention also provides means to isolate a group of relatedchemokines displaying both distinctness and similarities in structure,expression, and function. Elucidation of many of the physiologicaleffects of the proteins will be greatly accelerated by the isolation andcharacterization of distinct species variants of the ligands. Inparticular, the present invention provides useful probes for identifyingadditional homologous genetic entities in different species.

The isolated genes will allow transformation of cells lacking expressionof a corresponding chemokine, e.g., either species types or cells whichlack corresponding ligands and exhibit negative background activity.Expression of transformed genes will allow isolation of antigenicallypure cell lines, with defined or single specie variants. This approachwill allow for more sensitive detection and discrimination of thephysiological effects of chemokine receptor proteins. Subcellularfragments, e.g., cytoplasts or membrane fragments, can be isolated andused.

Dissection of critical structural elements which effect the variousdifferentiation functions provided by ligands is possible using standardtechniques of modern molecular biology, particularly in comparingmembers of the related class. See, e.g., the homolog-scanningmutagenesis technique described in Cunningham, et al. (1989) Science243:1339-1336; and approaches used in O'Dowd, et al. (1988) J. Biol.Chem. 263:15985-15992; and Lechleiter, et al. (1990) EMBO J.9:4381-4390.

In addition, receptor binding segments can be substituted betweenspecies variants to determine what structural features are important inboth receptor binding affinity and specificity, as well as signaltransduction. An array of different chemokine variants will be used toscreen for ligands exhibiting combined properties of interaction withdifferent receptor species variants.

Intracellular functions would probably involve segments of the receptorwhich are normally accessible to the cytosol. However, ligandinternalization may occur under certain circumstances, and interactionbetween intracellular components and “extracellular” segments may occur.The specific segments of interaction of a particular chemokine withother intracellular components may be identified by mutagenesis ordirect biochemical means, e.g., cross-linking or affinity methods.Structural analysis by crystallographic or other physical methods willalso be applicable. Further investigation of the mechanism of signaltransduction will include study of associated components which may beisolatable by affinity methods or by genetic means, e.g.,complementation analysis of mutants.

Further study of the expression and control of the various chemokineswill be pursued. The controlling elements associated with the proteinsmay exhibit differential developmental, tissue specific, or otherexpression patterns. Upstream or downstream genetic regions, e.g.,control elements, are of interest. Differential splicing of message maylead to membrane bound forms, soluble forms, and modified versions ofligand.

Structural studies of the proteins will lead to design of new ligands,particularly analogs exhibiting agonist or antagonist properties on thereceptor. This can be combined with previously described screeningmethods to isolate ligands exhibiting desired spectra of activities.

Expression in other cell types will often result in glycosylationdifferences in a particular chemokine. Various species variants mayexhibit distinct functions based upon structural differences other thanamino acid sequence. Differential modifications may be responsible fordifferential function, and elucidation of the effects are now madepossible.

Thus, the present invention provides important reagents related to aphysiological chemokine-binding protein interaction. Although theforegoing description has focused primarily upon the mouse and humanembodiments of the chemokines specifically described, those of skill inthe art will immediately recognize that the invention provides otherspecies counterparts, e.g., rat and other mammalian species or allelicor polymorphic variants.

V. Antibodies

Antibodies can be raised to these chemokines, including species orpolymorphic variants, and fragments thereof, both in their naturallyoccurring forms and in their recombinant forms. Additionally, antibodiescan be raised to chemokines in either their active forms or in theirinactive forms. Anti-idiotypic antibodies are also contemplated.

Antibodies, including binding fragments and single chain versions,against predetermined fragments of the ligands can be raised byimmunization of animals with concatemers or conjugates of the fragmentswith immunogenic proteins. Monoclonal antibodies are prepared from cellssecreting the desired antibody. These antibodies can be screened forbinding to normal or defective chemokines, or screened for agonistic orantagonistic activity, e.g., mediated through a receptor for achemokine. These monoclonal antibodies will usually bind with at least aK_(D) of about 1 mM, more usually at least about 300 μM, typically atleast about 10 μM, more typically at least about 30 μM, preferably atleast about 10 μM, and more preferably at least about 3 μM or better.

The antibodies, including antigen binding fragments, of this inventioncan have significant diagnostic or therapeutic value. They can be potentantagonists that bind to ligand and inhibit binding to receptor orinhibit the ability of a ligand to elicit a biological response. Theyalso can be useful as non-neutralizing antibodies and can be coupled totoxins or radionuclides so that when the antibody binds to ligand, acell expressing it, e.g., on its surface via receptor, is killed.Further, these antibodies can be conjugated to drugs or othertherapeutic agents, either directly or indirectly by means of a linker,and may effect drug targeting. Antibodies to receptors may be moreeasily used to block ligand binding and signal transduction.

The antibodies of this invention can also be useful in diagnostic orreagent purification applications. As capture or non-neutralizingantibodies, they can be screened for ability to bind to the chemokineswithout inhibiting receptor binding. As neutralizing antibodies, theycan be useful in competitive binding assays. They will also be useful indetecting or quantifying chemokine or, indirectly, receptors, e.g., inimmunoassays. They may be used as purification reagents inimmunoaffinity columns or as immunohistochemistry reagents.

Ligand fragments may be concatenated or joined to other materials,particularly polypeptides, as fused or covalently joined polypeptides tobe used as immunogens. Short peptides will preferably be made as repeatstructures to increase size. A ligand and its fragments may be fused orcovalently linked to a variety of immunogens, such as keyhole limpethemocyanin, bovine serum albumin, tetanus toxoid, etc. See Microbiology,Hoeber Medical Division, Harper and Row, 1969; Landsteiner (1962)Specificity of Serological Reactions, Dover Publications, New York, andWilliams, et al. (1967) Methods in Immunology and Immunochemistry, Vol.1, Academic Press, New York, for descriptions of methods of preparingpolyclonal antisera. A typical method involves hyperimmunization of ananimal with an antigen. The blood of the animal is then collectedshortly after the repeated immunizations and the gamma globulin fractionis isolated.

In some instances, it is desirable to prepare monoclonal antibodies fromvarious mammalian hosts, such as mice, rodents, primates, humans, etc.Description of techniques for preparing such monoclonal antibodies maybe found in, e.g., Stites, et al. (eds.) Basic and Clinical Immunology(4th ed.), Lange Medical Publications, Los Altos, Calif., and referencescited therein; Harlow and Lane (1988) Antibodies: A Laboratory Manual,CSH Press; Goding (1986) Monoclonal Antibodies: Principles and Practice(2d ed.) Academic Press, New York; and particularly in Kohler andMilstein (1975) in Nature 256:495-497, which discusses one method ofgenerating monoclonal antibodies. Summarized briefly, this methodinvolves injecting an animal with an immunogen. The animal is thensacrificed and cells taken, e.g., from its spleen, which are then fusedwith myeloma cells. The result is a hybrid cell or “hybridoma” that iscapable of reproducing in vitro. The population of hybridomas is thenscreened to isolate individual clones, each of which secrete a singleantibody species to the immunogen. In this manner, the individualantibody species obtained are the products of immortalized and clonedsingle B cells from the immune animal generated in response to aspecific site recognized on the immunogenic substance. Large amounts ofantibody may be derived from ascites fluid from an animal.

Other suitable techniques involve in vitro exposure of lymphocytes tothe antigenic polypeptides or alternatively to selection of libraries ofantibodies in phage or similar vectors. See, Huse, et al. (1989)“Generation of a Large Combinatorial Library of the ImmunoglobulinRepertoire in Phage Lambda,” Science 246:1275-1281; and Ward, et al.(1989) Nature 341:544-546. The polypeptides and antibodies of thepresent invention may be used with or without modification, includingchimeric or humanized antibodies. Frequently, the polypeptides andantibodies will be labeled by joining, either covalently ornon-covalently, a substance which provides for a detectable signal. Awide variety of labels and conjugation techniques are known and arereported extensively in both the scientific and patent literature.Suitable labels include radionuclides, enzymes, substrates, cofactors,inhibitors, fluorescent moieties, chemiluminescent moieties, magneticparticles, and the like. Patents, teaching the use of such labelsinclude U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345;4,277,437; 4,275,149; and 4,366,241. Also, recombinant immunoglobulinsmay be produced, see Cabilly, U.S. Pat. No. 4,816,567; and Queen et al.(1989) Proc. Nat'l. Acad. Sci. 86:10029-10033.

The antibodies of this invention can also be used for affinitychromatography in isolating the protein. Columns can be prepared wherethe antibodies are linked to a solid support, e.g., particles, such asagarose, Sephadex, or the like, where a cell lysate may be passedthrough the column, the column washed, followed by increasingconcentrations of a mild denaturant, whereby the purified chemokineprotein will be released.

The antibodies may also be used to screen expression libraries forparticular expression products. Usually the antibodies used in such aprocedure will be labeled with a moiety allowing easy detection ofpresence of antigen by antibody binding.

Antibodies raised against these chemokine will also be useful to raiseanti-idiotypic antibodies. These will be useful in detecting ordiagnosing various immunological conditions related to expression of therespective antigens.

VI. Nucleic Acids

The described peptide sequences and the related reagents are useful inisolating a DNA clone encoding these chemokines, e.g., from a naturalsource. Typically, it will be useful in isolating a gene from anotherindividual, and similar procedures will be applied to isolate genes fromother species, e.g., warm blooded animals, such as birds and mammals.Cross hybridization will allow isolation of ligand from other species. Anumber of different approaches should be available to successfullyisolate a suitable nucleic acid clone. Similar concepts apply to thereceptor embodiments.

The purified protein or defined peptides are useful for generatingantibodies by standard methods, as described above. Synthetic peptidesor purified protein can be presented to an immune system to generatemonoclonal or polyclonal antibodies. See, e.g., Coligan (1991) CurrentProtocols in Immunology Wiley/Greene; and Harlow and Lane (1989)Antibodies: A Laboratory Manual Cold Spring Harbor Press. Alternatively,a chemokine receptor can be used as a specific binding reagent, andadvantage can be taken of its specificity of binding, much like anantibody would be used. However, chemokine receptors are typically 7transmembrane proteins, which could be sensitive to appropriateinteraction with lipid or membrane. The signal transduction typically ismediated through a G-protein.

For example, the specific binding composition could be used forscreening of an expression library made from a cell line which expressesa particular chemokine. The screening can be standard staining ofsurface expressed ligand, or by panning. Screening of intracellularexpression can also be performed by various staining orimmunofluorescence procedures. The binding compositions could be used toaffinity purify or sort out cells expressing the ligand.

The peptide segments can also be used to predict appropriateoligonucleotides to screen a library, e.g., to isolate species variants.The genetic code can be used to select appropriate oligonucleotidesuseful as probes for screening. See, e.g., Tables 1 through 5. Incombination with polymerase chain reaction (PCR) techniques, syntheticoligonucleotides will be useful in selecting correct clones from alibrary. Complementary sequences will also be used as probes or primers.Based upon identification of the likely amino terminus, the thirdpeptide should be particularly useful, e.g., coupled with anchoredvector or poly-A complementary PCR techniques or with complementary DNAof other peptides.

This invention contemplates use of isolated DNA or fragments to encode abiologically active corresponding chemokine polypeptide. In addition,this invention covers isolated or recombinant DNA which encodes abiologically active protein or polypeptide which is capable ofhybridizing under appropriate conditions with the DNA sequencesdescribed herein. Said biologically active protein or polypeptide can bean intact ligand, or fragment, and have an amino acid sequence asdisclosed in Tables 1 through 3. Further, this invention covers the useof isolated or recombinant DNA, or fragments thereof, which encodeproteins which are homologous to a chemokine or which was isolated usingcDNA encoding a chemokine as a probe. The isolated DNA can have therespective regulatory sequences in the 5′ and 3′ flanks, e.g.,promoters, enhancers, poly-A addition signals, and others.Alternatively, promoters or other regulatory signals may be incorporatedto be operably linked to natural genes in a cell.

An “isolated” nucleic acid is a nucleic acid, e.g., an RNA, DNA, or amixed polymer, which is substantially separated from other componentswhich naturally accompany a native sequence, e.g., ribosomes,polymerases, and flanking genomic sequences from the originatingspecies. The term embraces a nucleic acid sequence which has beenremoved from its naturally occurring environment, and includesrecombinant or cloned DNA isolates and chemically synthesized analogs oranalogs biologically synthesized by heterologous systems. Asubstantially pure molecule includes isolated forms of the molecule.

An isolated nucleic acid will generally be a homogeneous composition ofmolecules, but will, in some embodiments, contain minor heterogeneity.This heterogeneity is typically found at the polymer ends or portionsnot critical to a desired biological function or activity.

A “recombinant” nucleic acid is defined either by its method ofproduction or its structure. In reference to its method of production,e.g., a product made by a process, the process is use of recombinantnucleic acid techniques, e.g., involving human intervention in thenucleotide sequence, typically selection or production. Alternatively,it can be a nucleic acid made by generating a sequence comprising fusionof two fragments which are not naturally contiguous to each other, butis meant to exclude products of nature, e.g., naturally occurringmutants. Thus, for example, products made by transforming cells with anyunnaturally occurring vector is encompassed, as are nucleic acidscomprising sequence derived using any synthetic oligonucleotide process.Such is often done to replace a codon with a redundant codon encodingthe same or a conservative amino acid, while typically introducing orremoving a sequence recognition site. Alternatively, it is performed tojoin together nucleic acid segments of desired functions to generate asingle genetic entity comprising a desired combination of functions notfound in the commonly available natural forms. Restriction enzymerecognition sites are often the target of such artificial manipulations,but other site specific targets, e.g., promoters, DNA replication sites,regulation sequences, control sequences, or other useful features may beincorporated by design. A similar concept is intended for a recombinant,e.g., fusion, polypeptide. Specifically included are synthetic nucleicacids which, by genetic code redundancy, encode polypeptides similar tofragments of these antigens, and fusions of sequences from variousdifferent species variants.

A significant “fragment” in a nucleic acid context is a contiguoussegment of at least about 17 nucleotides, generally at least about 20nucleotides, more generally at least about 23 nucleotides, ordinarily atleast about 26 nucleotides, more ordinarily at least about 29nucleotides, often at least about 32 nucleotides, more often at leastabout 35 nucleotides, typically at least about 38 nucleotides, moretypically at least about 41 nucleotides, usually at least about 44nucleotides, more usually at least about 47 nucleotides, preferably atleast about 50 nucleotides, more preferably at least about 53nucleotides, and in particularly preferred embodiments will be at leastabout 56 or more nucleotides, e.g., 60, 65, 75, 85, 100, 120, 150, 200,250, 300, 400, etc. Such fragments may have ends which begin and/or endat virtually all positions, e.g., beginning at nucleotides 1, 2, 3,etc., and ending at, e.g., 300, 299, 298, 287, etc., in allcombinations. Particularly interesting polynucleotides have endscorresponding to structural domain boundaries.

A DNA which codes for a particular chemokine protein or peptide will bevery useful to identify genes, mRNA, and cDNA species which code forrelated or homologous ligands, as well as DNAs which code for homologousproteins from different species. There are likely homologs in otherspecies, including primates. Various chemokine proteins should behomologous and are encompassed herein. However, even proteins that havea more distant evolutionary relationship to the ligand can readily beisolated under appropriate conditions using these sequences if they aresufficiently homologous. Primate chemokines are of particular interest.

This invention further covers recombinant DNA molecules and fragmentshaving a DNA sequence identical to or highly homologous to the isolatedDNAs set forth herein. In particular, the sequences will often beoperably linked to DNA segments which control transcription,translation, and DNA replication. Alternatively, recombinant clonesderived from the genomic sequences, e.g., containing introns, will beuseful for transgenic studies, including, e.g., transgenic cells andorganisms, and for gene therapy. See, e.g., Goodnow (1992) “TransgenicAnimals” in Roitt (ed.) Encyclopedia of Immunology Academic Press, SanDiego, pp. 1502-1504; Travis (1992) Science 256:1392-1394; Kuhn, et al.(1991) Science 254:707-710; Capecchi (1989) Science 244:1288; Robertson(1987) (ed.) Teratocarcinomas and Embryonic Stem Cells: A PracticalApproach IRL Press, Oxford; and Rosenberg (1992) J. Clinical Oncology10:180-199.

Homologous nucleic acid sequences, when compared, exhibit significantsimilarity, or identity. The standards for homology in nucleic acids areeither measures for homology generally used in the art by sequencecomparison or based upon hybridization conditions. The hybridizationconditions are described in greater detail below.

Substantial homology in the nucleic acid sequence comparison contextmeans either that the segments, or their complementary strands, whencompared, are identical when optimally aligned, with appropriatenucleotide insertions or deletions, in at least about 50% of thenucleotides, generally at least about 56%, more generally at least about59%, ordinarily at least about 62%, more ordinarily at least about 65%,often at least about 68%, more often at least about 71%, typically atleast about 74%, more typically at least about 77%, usually at leastabout 80%, more usually at least about 85%, preferably at least about90%, more preferably at least about 95 to 98% or more, and in particularembodiments, as high at about 99% or more of the nucleotides.Alternatively, substantial homology exists when the segments willhybridize under selective hybridization conditions, to a strand, or itscomplement, typically using a sequence derived from Tables 1 through 5.Typically, selective hybridization will occur when there is at leastabout 55% homology over a stretch of at least about 30 nucleotides,preferably at least about 65% over a stretch of at least about 25nucleotides, more preferably at least about 75%, and most preferably atleast about 90% over about 20 nucleotides. See, Kanehisa (1984) Nuc.Acids Res. 12:203-213. The length of homology comparison, as described,may be over longer stretches, and in certain embodiments will be over astretch of at least about 17 nucleotides, usually at least about 20nucleotides, more usually at least about 24 nucleotides, typically atleast about 28 nucleotides, more typically at least about 40nucleotides, preferably at least about 50 nucleotides, and morepreferably at least about 75 to 100 or more nucleotides.

Stringent conditions, in referring to homology in the hybridizationcontext, will be stringent combined conditions of salt, temperature,organic solvents, and other parameters, typically those controlled inhybridization reactions. Stringent temperature conditions will usuallyinclude temperatures in excess of about 30° C., more usually in excessof about 37° C., typically in excess of about 45° C., more typically inexcess of about 55° C., preferably in excess of about 65° C., and morepreferably in excess of about 70° C. Stringent salt conditions willordinarily be less than about 1000 mM, usually less than about 500 mM,more usually less than about 400 mM, typically less than about 300 mM,preferably less than about 200 mM, and more preferably less than about150 mM. However, the combination of parameters is much more importantthan the measure of any single parameter. See, e.g., Wetmur and Davidson(1968) J. Mol. Biol. 31:349-370.

Corresponding chemokines from other mammalian species can be cloned andisolated by cross-species hybridization of closely related species.Alternatively, sequences from a data base may be recognized as havingsimilarity. Homology may be relatively low between distantly relatedspecies, and thus hybridization of relatively closely related species isadvisable. Alternatively, preparation of an antibody preparation whichexhibits less species specificity may be useful in expression cloningapproaches. PCR approaches using segments of conserved sequences willalso be used.

VII. Making Chemokines, Receptors; Mimetics

DNA which encodes each respective chemokine or fragments thereof can beobtained by chemical synthesis, screening cDNA libraries, or byscreening genomic libraries prepared from a wide variety of cell linesor tissue samples.

This DNA can be expressed in a wide variety of host cells for thesynthesis of a full-length ligand or fragments which can in turn, forexample, be used to generate polyclonal or monoclonal antibodies; forbinding studies; for construction and expression of modified molecules;and for structure/function studies. Each antigen or its fragments can beexpressed in host cells that are transformed or transfected withappropriate expression vectors. These molecules can be substantiallypurified to be free of protein or cellular contaminants, other thanthose derived from the recombinant host, and therefore are particularlyuseful in pharmaceutical compositions when combined with apharmaceutically acceptable carrier and/or diluent. The antigen, orportions thereof, may be expressed as fusions with other proteins.

Expression vectors are typically self-replicating DNA or RNA constructscontaining the desired antigen gene or its fragments, usually operablylinked to suitable genetic control elements that are recognized in asuitable host cell. These control elements are capable of effectingexpression within a suitable host. The specific type of control elementsnecessary to effect expression will depend upon the eventual host cellused. Generally, the genetic control elements can include a prokaryoticpromoter system or a eukaryotic promoter expression control system, andtypically include a transcriptional promoter, an optional operator tocontrol the onset of transcription, transcription enhancers to elevatethe level of mRNA expression, a sequence that encodes a suitableribosome binding site, and sequences that terminate transcription andtranslation. Expression vectors also usually contain an origin ofreplication that allows the vector to replicate independently of thehost cell.

The vectors of this invention contain DNA which encode embodiments of achemokine, receptor, or a fragment thereof, typically encoding abiologically active polypeptide. The DNA can be under the control of aviral promoter and can encode a selection marker. This invention furthercontemplates use of such expression vectors which are capable ofexpressing eukaryotic cDNA coding for each chemokine in a prokaryotic oreukaryotic host, where the vector is compatible with the host and wherethe eukaryotic cDNA coding for the ligand is inserted into the vectorsuch that growth of the host containing the vector expresses the cDNA inquestion. Usually, expression vectors are designed for stablereplication in their host cells or for amplification to greatly increasethe total number of copies of the desirable gene per cell. It is notalways necessary to require that an expression vector replicate in ahost cell, e.g., it is possible to effect transient expression of theligand or its fragments in various hosts using vectors that do notcontain a replication origin that is recognized by the host cell. It isalso possible to use vectors that cause integration of a chemokine geneor its fragments into the host DNA by recombination, or to integrate apromoter which controls expression of an endogenous gene.

Vectors, as used herein, comprise plasmids, viruses, bacteriophage,integratable DNA fragments, and other vehicles which enable theintegration of DNA fragments into the genome of the host. Expressionvectors are specialized vectors which contain genetic control elementsthat effect expression of operably linked genes. Plasmids are the mostcommonly used form of vector but all other forms of vectors which servean equivalent function and which are, or become, known in the art aresuitable for use herein. See, e.g., Pouwels, et al. (1985 andSupplements) Cloning Vectors: A Laboratory Manual, Elsevier, N.Y., andRodriquez, et al. (1988) (eds.) Vectors: A Survey of Molecular CloningVectors and Their Uses, Buttersworth, Boston, Mass.

Transformed cells include cells, preferably mammalian, that have beentransformed or transfected with a chemokine gene containing vectorconstructed using recombinant DNA techniques. Transformed host cellsusually express the ligand or its fragments, but for purposes ofcloning, amplifying, and manipulating its DNA, do not need to expressthe protein. This invention further contemplates culturing transformedcells in a nutrient medium, thus permitting the protein to accumulate inthe culture. The protein can be recovered, either from the culture orfrom the culture medium.

For purposes of this invention, DNA sequences are operably linked whenthey are functionally related to each other. For example, DNA for apresequence or secretory leader is operably linked to a polypeptide ifit is expressed as a preprotein or participates in directing thepolypeptide to the cell membrane or in secretion of the polypeptide. Apromoter is operably linked to a coding sequence if it controls thetranscription of the polypeptide; a ribosome binding site is operablylinked to a coding sequence if it is positioned to permit translation.Usually, operably linked means contiguous and in reading frame, however,certain genetic elements such as repressor genes are not contiguouslylinked but still bind to operator sequences that in turn controlexpression.

Suitable host cells include prokaryotes, lower eukaryotes, and highereukaryotes. Prokaryotes include both gram negative and gram positiveorganisms, e.g., E. coli and B. subtilis. Lower eukaryotes includeyeasts, e.g., S. cerevisiae and Pichia, and species of the genusDictyostelium. Higher eukaryotes include established tissue culture celllines from animal cells, both of non-mammalian origin, e.g., insectcells, and birds, and of mammalian origin, e.g., human, primates, androdents.

Prokaryotic host-vector systems include a wide variety of vectors formany different species. As used herein, E. coli and its vectors will beused generically to include equivalent vectors used in otherprokaryotes. A representative vector for amplifying DNA is pBR322 ormany of its derivatives. Vectors that can be used to express thesechemokines or their fragments include, but are not limited to, suchvectors as those containing the lac promoter (pUC-series); trp promoter(pBR322-trp); Ipp promoter (the pIN-series); lambda-pP or pR promoters(pOTS); or hybrid promoters such as ptac (pDR540). See Brosius, et al.(1988) “Expression Vectors Employing Lambda-, trp-, lac-, andIpp-derived Promoters”, in Rodriguez and Denhardt (eds.) Vectors: ASurvey of Molecular Cloning Vectors and Their Uses, Buttersworth,Boston, Chapter 10, pp. 205-236.

Lower eukaryotes, e.g., yeasts and Dictyostelium, may be transformedwith chemokine sequence containing vectors. For purposes of thisinvention, the most common lower eukaryotic host is the baker's yeast,Saccharomyces cerevisiae. It will be used to generically represent lowereukaryotes although a number of other strains and species are alsoavailable. Yeast vectors typically consist of a replication origin(unless of the integrating type), a selection gene, a promoter, DNAencoding the desired protein or its fragments, and sequences fortranslation termination, polyadenylation, and transcription termination.Suitable expression vectors for yeast include such constitutivepromoters as 3-phosphoglycerate kinase and various other glycolyticenzyme gene promoters or such inducible promoters as the alcoholdehydrogenase 2 promoter or metallothionine promoter. Suitable vectorsinclude derivatives of the following types: self-replicating low copynumber (such as the YRp-series), self-replicating high copy number (suchas the YEp-series); integrating types (such as the YIp-series), ormini-chromosomes (such as the YCp-series).

Higher eukaryotic tissue culture cells are the preferred host cells forexpression of the functionally active chemokine protein. In principle,most any higher eukaryotic tissue culture cell line is workable, e.g.,insect baculovirus expression systems, whether from an invertebrate orvertebrate source. However, mammalian cells are preferred, in that theprocessing, both cotranslationally and posttranslationally.Transformation or transfection and propagation of such cells has becomea routine procedure. Examples of useful cell lines include HeLa cells,Chinese hamster ovary (CHO) cell lines, baby rat kidney (BRK) celllines, insect cell lines, bird cell lines, and monkey (COS) cell lines.Expression vectors for such cell lines usually include an origin ofreplication, a promoter, a translation initiation site, RNA splice sites(if genomic DNA is used), a polyadenylation site, and a transcriptiontermination site. These vectors also usually contain a selection gene oramplification gene. Suitable expression vectors may be plasmids,viruses, or retroviruses carrying promoters derived, e.g., from suchsources as from adenovirus, SV40, parvoviruses, vaccinia virus, orcytomegalovirus. Representative examples of suitable expression vectorsinclude pcDNA1; pCD, see Okayama, et al. (1985) Mol. Cell Biol.5:1136-1142; pMClneo Poly-A, see Thomas, et al. (1987) Cell 51:503-512;and a baculovirus vector such as pAC 373 or pAC 610.

It will often be desired to express a chemokine polypeptide in a systemwhich provides a specific or defined glycosylation pattern. In thiscase, the usual pattern will be that provided naturally by theexpression system. However, the pattern will be modifiable by exposingthe polypeptide, e.g., an unglycosylated form, to appropriateglycosylating proteins introduced into a heterologous expression system.For example, a chemokine gene may be co-transformed with one or moregenes encoding mammalian or other glycosylating enzymes. Using thisapproach, certain mammalian glycosylation patterns will be achievable orapproximated in prokaryote or other cells.

A chemokine, or a fragment thereof, may be engineered to be phosphatidylinositol (PI) linked to a cell membrane, but can be removed frommembranes by treatment with a phosphatidyl inositol cleaving enzyme,e.g., phosphatidyl inositol phospholipase-C. This releases the antigenin a biologically active form, and allows purification by standardprocedures of protein chemistry. See, e.g., Low (1989) Biochim. Biophys.Acta 988:427-454; Tse, et al. (1985) Science 230:1003-1008; and Brunner,et al. (1991) J. Cell Biol. 114:1275-1283.

Now that these chemokines have been characterized, fragments orderivatives thereof can be prepared by conventional processes forsynthesizing peptides. These include processes such as are described inStewart and Young (1984) Solid Phase Peptide Synthesis, Pierce ChemicalCo., Rockford, Ill.; Bodanszky and Bodanszky (1984) The Practice ofPeptide Synthesis, Springer-Verlag, New York; and Bodanszky (1984) ThePrinciples of Peptide Synthesis, Springer-Verlag, New York. For example,an azide process, an acid chloride process, an acid anhydride process, amixed anhydride process, an active ester process (for example,p-nitrophenyl ester, N-hydroxysuccinimide ester, or cyanomethyl ester),a carbodiimidazole process, an oxidative-reductive process, or adicyclohexylcarbodiimide (DCCD)/additive process can be used. Solidphase and solution phase syntheses are both applicable to the foregoingprocesses.

These chemokines, fragments, or derivatives are suitably prepared inaccordance with the above processes as typically employed in peptidesynthesis, generally either by a so-called stepwise process whichcomprises condensing an amino acid to the terminal amino acid, one byone in sequence, or by coupling peptide fragments to the terminal aminoacid. Amino groups that are not being used in the coupling reaction aretypically protected to prevent coupling at an incorrect location.

If a solid phase synthesis is adopted, the C-terminal amino acid istypically bound to an insoluble carrier or support through its carboxylgroup. The insoluble carrier is not particularly limited as long as ithas a binding capability to a reactive carboxyl group. Examples of suchinsoluble carriers include halomethyl resins, such as chloromethyl resinor bromomethyl resin, hydroxymethyl resins, phenol resins,tert-alkyloxycarbonyl-hydrazidated resins, and the like.

An amino group-protected amino acid is bound in sequence throughcondensation of its activated carboxyl group and the reactive aminogroup of the previously formed peptide or chain, to synthesize thepeptide step by step. After synthesizing the complete sequence, thepeptide is split off from the insoluble carrier to produce the peptide.This solid-phase approach is generally described by Merrifield, et al.(1963) in J. Am. Chem. Soc. 85:2149-2156.

The prepared ligand and fragments thereof can be isolated and purifiedfrom the reaction mixture by means of peptide separation, e.g., byextraction, precipitation, electrophoresis and various forms ofchromatography, and the like. The various chemokines of this inventioncan be obtained in varying degrees of purity depending upon its desireduse. Purification can be accomplished by use of the protein purificationtechniques disclosed herein or by the use of the antibodies hereindescribed, e.g., in immunoabsorbent affinity chromatography. Thisimmunoabsorbent affinity chromatography is carried out by first linkingthe antibodies to a solid support and then contacting the linkedantibodies with solubilized lysates of appropriate source cells, lysatesof other cells expressing the ligand, or lysates or supernatants ofcells producing the desired chemokine as a result of DNA techniques, seebelow.

VIII. Uses

The present invention provides reagents which will find use indiagnostic applications as described elsewhere herein, e.g., in thegeneral description for developmental abnormalities, or below in thedescription of kits for diagnosis.

This invention also provides reagents with significant therapeuticvalue. These chemokines (naturally occurring or recombinant), fragmentsthereof and antibodies thereto, along with compounds identified ashaving binding affinity to them, should be useful in the treatment ofconditions associated with abnormal physiology or development, includinginflammatory conditions, including asthma. In particular, modulation oftrafficking of leukocytes is one likely biological activity, but a widertissue distribution might suggest broader biological activity,including, e.g., antiviral effects. Abnormal proliferation,regeneration, degeneration, and atrophy may be modulated by appropriatetherapeutic treatment using the compositions provided herein. Forexample, a disease or disorder associated with abnormal expression orabnormal signaling by a chemokine should be a likely target for anagonist or antagonist of the ligand.

Various abnormal physiological or developmental conditions are known incell types shown to possess the chemokine mRNAs by Northern blotanalysis. See Berkow (ed.) The Merck Manual of Diagnosis and Therapy,Merck & Co., Rahway, N.J.; and Thorn, et al. Harrison's Principles ofInternal Medicine, McGraw-Hill, N.Y. Developmental or functionalabnormalities, e.g., of the immune system, cause significant medicalabnormalities and conditions which may be susceptible to prevention ortreatment using compositions provided herein.

Chemokine antibodies, including recombinant forms, can be purified andthen administered to a patient. These reagents can be combined fortherapeutic use with additional active or inert ingredients, e.g., inconventional pharmaceutically acceptable carriers or diluents, e.g.,immunogenic adjuvants, along with physiologically innocuous stabilizersand excipients. These combinations can be sterile filtered and placedinto dosage forms as by lyophilization in dosage vials or storage instabilized aqueous preparations. This invention also contemplates use ofantibodies or binding fragments thereof, including forms which are notcomplement binding. Moreover, modifications to the antibody molecules orantigen binding fragments thereof, may be adopted which affect thepharmacokinetics or pharmacodynamics of the therapeutic entity.

Drug screening using antibodies or receptor or fragments thereof can beperformed to identify compounds having binding affinity to eachchemokine or receptor, including isolation of associated components.Subsequent biological assays can then be utilized to determine if thecompound has intrinsic stimulating activity and is therefore a blockeror antagonist in that it blocks the activity of the ligand. Likewise, acompound having intrinsic stimulating activity can activate the receptorand is thus an agonist in that it simulates the activity of a chemokine.This invention further contemplates the therapeutic use of antibodies tothese chemokines as antagonists. This approach should be particularlyuseful with other chemokine species variants.

The quantities of reagents necessary for effective therapy will dependupon many different factors, including means of administration, targetsite, physiological state of the patient, and other medicantsadministered. Thus, treatment dosages should be titrated to optimizesafety and efficacy in various populations, including racial subgroups,age, gender, etc. Typically, dosages used in vitro may provide usefulguidance in the amounts useful for in situ administration of thesereagents. Animal testing of effective doses for treatment of particulardisorders will provide further predictive indication of human dosage.Various considerations are described, e.g., in Gilman, et al. (eds.)(1990) Goodman and Gilman's: The Pharmacological Bases of Therapeutics,8th Ed., Pergamon Press; and Remington's Pharmaceutical Sciences, 17thed. (1990), Mack Publishing Co., Easton, Pa. Methods for administrationare discussed therein and below, e.g., for oral, intravenous,intraperitoneal, or intramuscular administration, transdermal diffusion,and others. Pharmaceutically acceptable carriers typically includewater, saline, buffers, and other compounds described, e.g., in theMerck Index, Merck & Co., Rahway, N.J. Dosage ranges would ordinarily beexpected to be in amounts lower than 1 mM concentrations, typically lessthan about 10 μM concentrations, usually less than about 100 nM,preferably less than about 10 pM (picomolar), and most preferably lessthan about 1 fM (femtomolar), with an appropriate carrier. Slow releaseformulations, or a slow release apparatus will often be utilized forcontinuous administration.

A chemokine, fragments thereof, or antibodies to it or its fragments,antagonists, and agonists, may be administered directly to the host tobe treated or, depending on the size of the compounds, it may bedesirable to conjugate them to carrier proteins such as ovalbumin orserum albumin prior to their administration. Therapeutic formulationsmay be administered in any conventional dosage formulation. While it ispossible for the active ingredient to be administered alone, it is oftenpreferable to present it as a pharmaceutical formulation. Formulationstypically comprise at least one active ingredient, as defined above,together with one or more acceptable carriers thereof. Each carriershould be both pharmaceutically and physiologically acceptable in thesense of being compatible with the other ingredients and not injuriousto the patient. Carriers may improve storage life, stability, etc.Formulations include those suitable for oral, rectal, nasal, orparenteral (including subcutaneous, intramuscular, intravenous andintradermal) administration. The formulations may conveniently bepresented in unit dosage form and may be prepared by any methods wellknown in the art of pharmacy. See, e.g., Gilman, et al. (eds.) (1990)Goodman and Gilman's: The Pharmacological Bases of Therapeutics, 8thEd., Pergamon Press; and Remington's Pharmaceutical Sciences, 17th ed.(1990), Mack Publishing Co., Easton, Pa.; Avis, et al. (eds.) (1993)Pharmaceutical Dosage Forms: Parenteral Medications Dekker, New York;Lieberman, et al. (eds.) (1990) Pharmaceutical Dosage Forms: TabletsDekker, New York; and Lieberman, et al. (eds.) (1990) PharmaceuticalDosage Forms Disperse Systems Dekker, New York. The therapy of thisinvention may be combined with or used in association with othertherapeutic agents.

Both the naturally occurring and the recombinant forms of the chemokinesof this invention are particularly useful in kits and assay methodswhich are capable of screening compounds for binding activity to theproteins. Several methods of automating assays have been developed inrecent years so as to permit screening of tens of thousands of compoundsin a short period. See, e.g., Fodor, et al. (1991) Science 251:767-773,which describes means for testing of binding affinity by a plurality ofdefined polymers synthesized on a solid substrate. The development ofsuitable assays can be greatly facilitated by the availability of largeamounts of purified, soluble chemokine as provided by this invention.

For example, antagonists can normally be found once the ligand has beenstructurally defined. Testing of potential ligand analogs is nowpossible upon the development of highly automated assay methods usingphysiologically responsive cells. In particular, new agonists andantagonists will be discovered by using screening techniques describedherein.

Viable cells could also be used to screen for the effects of drugs onrespective chemokine mediated functions, e.g., second messenger levels,i.e., Ca⁺⁺; inositol phosphate pool changes (see, e.g., Berridge (1993)Nature 361:315-325 or Billah and Anthes (1990) Biochem. J. 269:281-291);cellular morphology modification responses; phosphoinositide lipidturnover; an antiviral response. and others. Some detection methodsallow for elimination of a separation step, e.g., a proximity sensitivedetection system. Calcium sensitive dyes will be useful for detectingCa⁺⁺ levels, with a fluorimeter or a fluorescence cell sortingapparatus.

Rational drug design may also be based upon structural studies of themolecular shapes of the chemokines and other effectors or analogs.Effectors may be other proteins which mediate other functions inresponse to ligand binding, or other proteins which normally interactwith the receptor. One means for determining which sites interact withspecific other proteins is a physical structure determination, e.g.,x-ray crystallography or 2 dimensional NMR techniques. These willprovide guidance as to which amino acid residues form molecular contactregions. For a detailed description of protein structural determination,see, e.g., Blundell and Johnson (1976) Protein Crystallography, AcademicPress, New York.

Purified chemokine can be coated directly onto plates for use in theaforementioned drug screening techniques. However, non-neutralizingantibodies to these ligands can be used as capture antibodies toimmobilize the respective ligand on the solid phase.

Similar concepts also apply to the chemokine receptor embodiments of theinvention.

IX. Kits

This invention also contemplates use of chemokine proteins, fragmentsthereof, peptides, and their fusion products in a variety of diagnostickits and methods for detecting the presence of ligand, antibodies, orchemokine receptors. Typically the kit will have a compartmentcontaining either a defined chemokine peptide or gene segment or areagent which recognizes one or the other, e.g., antibodies.

A kit for determining the binding affinity of a test compound to achemokine would typically comprise a test compound; a labeled compound,for example an antibody having known binding affinity for the ligand; asource of chemokine (naturally occurring or recombinant); and a meansfor separating bound from free labeled compound, such as a solid phasefor immobilizing the ligand. Once compounds are screened, those havingsuitable binding affinity to the ligand can be evaluated in suitablebiological assays, as are well known in the art, to determine whetherthey act as agonists or antagonists to the receptor. The availability ofrecombinant chemokine polypeptides also provide well defined standardsfor calibrating such assays or as positive control samples.

A preferred kit for determining the concentration of, for example, achemokine in a sample would typically comprise a labeled compound, e.g.,antibody, having known binding affinity for the ligand, a source ofligand (naturally occurring or recombinant) and a means for separatingthe bound from free labeled compound, for example, a solid phase forimmobilizing the chemokine. Compartments containing reagents, andinstructions for use or disposal, will normally be provided.

Antibodies, including antigen binding fragments, specific for thechemokine or ligand fragments are useful in diagnostic applications todetect the presence of elevated levels of chemokine and/or itsfragments. Such diagnostic assays can employ lysates, live cells, fixedcells, immunofluorescence, cell cultures, body fluids, and further caninvolve the detection of antigens related to the ligand in serum, or thelike. Diagnostic assays may be homogeneous (without a separation stepbetween free reagent and antigen-ligand complex) or heterogeneous (witha separation step). Various commercial assays exist, such asradioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA),enzyme immunoassay (EIA), enzyme-multiplied immunoassay technique(EMIT), substrate-labeled fluorescent immunoassay (SLFIA), and the like.For example, unlabeled antibodies can be employed by using a secondantibody which is labeled and which recognizes the antibody to achemokine or to a particular fragment thereof. Similar assays have alsobeen extensively discussed in the literature. See, e.g., Harlow and Lane(1988) Antibodies: A Laboratory Manual, CSH.

Anti-idiotypic antibodies may have similar uses to diagnose presence ofantibodies against a chemokine, as such may be diagnostic of variousabnormal states. For example, overproduction of a chemokine may resultin production of various immunological reactions which may be diagnosticof abnormal physiological states, particularly in various inflammatoryor asthma conditions.

Frequently, the reagents for diagnostic assays are supplied in kits, soas to optimize the sensitivity of the assay. For the subject invention,depending upon the nature of the assay, the protocol, and the label,either labeled or unlabeled antibody or labeled chemokine is provided.This is usually in conjunction with other additives, such as buffers,stabilizers, materials necessary for signal production such assubstrates for enzymes, and the like. Preferably, the kit will alsocontain instructions for proper use and disposal of the contents afteruse. Typically the kit has compartments for each useful reagent.Desirably, the reagents are provided as a dry lyophilized powder, wherethe reagents may be reconstituted in an aqueous medium providingappropriate concentrations of reagents for performing the assay.

The aforementioned constituents of the drug screening and the diagnosticassays may be used without modification or may be modified in a varietyof ways. For example, labeling may be achieved by covalently ornon-covalently joining a moiety which directly or indirectly provides adetectable signal. In any of these assays, the ligand, test compound,chemokine, or antibodies thereto can be labeled either directly orindirectly. Possibilities for direct labeling include label groups:radiolabels such as ¹²⁵I, enzymes (U.S. Pat. No. 3,645,090) such asperoxidase and alkaline phosphatase, and fluorescent labels (U.S. Pat.No. 3,940,475) capable of monitoring the change in fluorescenceintensity, wavelength shift, or fluorescence polarization. Possibilitiesfor indirect labeling include biotinylation of one constituent followedby binding to avidin coupled to one of the above label groups.

There are also numerous methods of separating bound from the freeligand, or alternatively bound from free test compound. The chemokinecan be immobilized on various matrixes followed by washing. Suitablematrixes include plastic such as an ELISA plate, filters, and beads.Methods of immobilizing the chemokine to a matrix include, withoutlimitation, direct adhesion to plastic, use of a capture antibody,chemical coupling, and biotin-avidin. The last step in this approachinvolves the precipitation of ligand/antibody complex by any of severalmethods including those utilizing, e.g., an organic solvent such aspolyethylene glycol or a salt such as ammonium sulfate. Other suitableseparation techniques include, without limitation, the fluoresceinantibody magnetizable particle method described in Rattle, et al. (1984)Clin. Chem. 30:1457-1461, and the double antibody magnetic particleseparation as described in U.S. Pat. No. 4,659,678.

Methods for linking proteins or their fragments to the various labelshave been extensively reported in the literature and do not requiredetailed discussion here. Many of the techniques involve the use ofactivated carboxyl groups either through the use of carbodiimide oractive esters to form peptide bonds, the formation of thioethers byreaction of a mercapto group with an activated halogen such aschloroacetyl, or an activated olefin such as maleimide, for linkage, orthe like. Fusion proteins will also find use in these applications.

Another diagnostic aspect of this invention involves use ofoligonucleotide or polynucleotide sequences taken from the sequence of achemokine. These sequences can be used as probes for detecting levels ofthe ligand message in samples from patients suspected of having anabnormal condition, e.g., an inflammatory or developmental problem. Thepreparation of both RNA and DNA nucleotide sequences, the labeling ofthe sequences, and the preferred size of the sequences has receivedample description and discussion in the literature. Normally anoligonucleotide probe should have at least about 14 nucleotides, usuallyat least about 18 nucleotides, and the polynucleotide probes may be upto several kilobases. Various labels may be employed, most commonlyradionuclides, particularly ³²P. However, other techniques may also beemployed, such as using biotin modified nucleotides for introductioninto a polynucleotide. The biotin then serves as the site for binding toavidin or antibodies, which may be labeled with a wide variety oflabels, such as radionuclides, fluorescers, enzymes, or the like.Alternatively, antibodies may be employed which can recognize specificduplexes, including DNA duplexes, RNA duplexes, DNA-RNA hybrid duplexes,or DNA-protein duplexes. The antibodies in turn may be labeled and theassay carried out where the duplex is bound to a surface, so that uponthe formation of duplex on the surface, the presence of antibody boundto the duplex can be detected. The use of probes to the novel anti-senseRNA may be carried out in any conventional techniques such as nucleicacid hybridization, plus and minus screening, recombinational probing,hybrid released translation (HRT), and hybrid arrested translation(HART). This also includes amplification techniques such as polymerasechain reaction (PCR).

Diagnostic kits which also test for the qualitative or quantitativepresence of other markers are also contemplated. Diagnosis or prognosismay depend on the combination of multiple indications used as markers.Thus, kits may test for combinations of markers. See, e.g., Viallet, etal. (1989) Progress in Growth Factor Res. 1:89-97.

X. Receptor

Having isolated a ligand binding partner of a specific interaction,methods exist for isolating the counter-partner. See, Gearing, et alEMBO J. 8:3667-4676 or McMahan, et al. (1991) EMBO J. 10:2821-2832. Forexample, means to label a chemokine without interfering with the bindingto its receptor can be determined. For example, an affinity label can befused to either the amino- or carboxy-terminus of the ligand. Anexpression library can be screened for specific binding of chemokine,e.g., by cell sorting, or other screening to detect subpopulations whichexpress such a binding component. See, e.g., Ho, et al. (1993) Proc.Nat'l Acad. Sci. 90:11267-11271. Alternatively, a panning method may beused. See, e.g., Seed and Aruffo (1987) Proc. Nat'l. Acad. Sci.84:3365-3369.

Protein cross-linking techniques with label can be applied to a isolatebinding partners of a chemokine. This would allow identification ofprotein which specifically interacts with a chemokine, e.g., in aligand-receptor like manner.

In various embodiments, new receptors designated DC CR and M/DC CR wereisolated. The sequences of the human constructs and product are providedin Tables 4 and 5. Similar means for making variants and fragments, atthe nucleotide level or at the protein level, and making antibodies willbe available as described above, directed primarily to the chemokineembodiments. Many similar or related uses to the ligands will be appliedto the receptors, as specific binding reagents. In particular, methodswill be applied to screening for specific ligands for each receptor.Many uses, including kits, will also be available through analogoustechniques.

The broad scope of this invention is best understood with reference tothe following examples, which are not intended to limit the invention tospecific embodiments.

EXAMPLES I. General Methods

Some of the standard methods are described or referenced, e.g., inManiatis, et al. (1982) Molecular Cloning, A Laboratory Manual, ColdSpring Harbor Laboratory, Cold Spring Harbor Press; Sambrook, et al.(1989) Molecular Cloning: A Laboratory Manual, (2d ed.), vols 1-3, CSHPress, NY; Ausubel, et al., Biology, Greene Publishing Associates,Brooklyn, N.Y.; or Ausubel, et al. (1987 and Supplements) CurrentProtocols in Molecular Biology, Greene/Wiley, New York; Innis, et al.(eds.) (1990) PCR Protocols: A Guide to Methods and ApplicationsAcademic Press, N.Y. Methods for protein purification include suchmethods as ammonium sulfate precipitation, column chromatography,electrophoresis, centrifugation, crystallization, and others. See, e.g.,Ausubel, et al. (1987 and periodic supplements); Deutscher (1990) “Guideto Protein Purification” in Methods in Enzymology, vol. 182, and othervolumes in this series; and manufacturer's literature on use of proteinpurification products, e.g., Pharmacia, Piscataway, N.J., or Bio-Rad,Richmond, Calif. Combination with recombinant techniques allow fusion toappropriate segments, e.g., to a FLAG sequence or an equivalent whichcan be fused via a protease-removable sequence. See, e.g., Hochuli(1989) Chemische Industrie 12:69-70; Hochuli (1990) “Purification ofRecombinant Proteins with Metal Chelate Absorbent” in Setlow (ed.)Genetic Engineering, Principle and Methods 12:87-98, Plenum Press, N.Y.;and Crowe, et al. (1992) QIAexpress: The High Level Expression & ProteinPurification System QUIAGEN, Inc., Chatsworth, Calif.

FACS analyses are described in Melamed, et al. (1990) Flow Cytometry andSorting Wiley-Liss, Inc., New York, N.Y.; Shapiro (1988) Practical FlowCytometry Liss, New York, N.Y.; and Robinson, et al. (1993) Handbook ofFlow Cytometry Methods Wiley-Liss, New York, N.Y.

II. Isolation and Characterization of Chemokine cDNAs

A. TECK

The TECK was isolated from a cDNA library made from thymus cells from aRAG-1 “knockout” mouse. See, Mombaerts, et al. (1992) Cell 68:869-877.Individual cDNA clones were sequenced using standard methods, e.g., theTaq DyeDeoxy Terminator Cycle Sequencing kit (Applied Biosystems, FosterCity, Calif.), and the TECK sequence was identified and furthercharacterized. Computer analyses with other C-C chemokine family membersrevealed significant homology at the amino acid levels with otherchemokines. The nucleotide sequence for mouse is provided in Table 1,encoding a polypeptide of about 144 amino acids. The signal sequenceshould run from 1 (met) to about 23 (ala), and removal of the signalsequence should provide one natural mature sequence beginning at 24(gln). Additional processing may occur in a physiological system.

The sequence is notable in having a longer carboxy-terminal tail thanmost other CC chemokines. TECK exhibits one glycosylation site, andseveral AAMP, PKC, and CK2 phosphorylation sites.

B. MIP-3α

The MIP-3α was isolated from a cDNA library made from human monocytesactivated with LPS and IFN-γ Individual cDNA clones were sequenced usingstandard methods, and the MIP-3α sequence was identified and furthercharacterized. The nucleotide sequence is provided in Table 2, encodinga polypeptide of at least about 89 amino acids. The signal sequenceshould run from about 1 (met) to 21 (cys), and removal of the signalsequence should provide one natural sequence beginning with gly.Additional processing may occur in a physiological system.

C. MIP-3β

The MIP-3β was isolated from a cDNA library made from human fetal lungcells. Individual cDNA clones are sequenced using standard methods, andthe MIP-3α sequence was identified and further characterized. Thenucleotide sequence is provided in Table 3, encoding a polypeptide ofabout 98 amino acids. The signal sequence should run from about 1 (met)to about 21 (ser), and removal of the signal sequence should provide onemature natural sequence beginning from gly. Additional processing mayoccur in a physiological system.

This chemokine has been paired with a receptor designated Ebil. SeeYoshida, et al. (1997) J. Biol. Chem. 13803-13809.

D. Dendritic Cell Receptor for Chemokine; DC CR

The DC CR was isolated from RNA made from dendritic cells isolated fromCD34⁺ cord blood cells, isolated by standard procedure. It was alsoisolated from eosinophils using degenerate PCR primers of the TM2 andTM7 segments, which are often conserved among chemokine receptors. Theseeosinophils were isolated by taking PBLs, depletion of red blood cellsby lysis, and negative selection of CD16 to remove neutrophils.

Sequencing of the PCR fragments indicated a potential novel receptor,and the fragment was used to isolate a full length clone byhybridization. Clone isolates were sequenced using standard methods, andthe DC CR sequence was identified and further characterized. Thenucleotide sequence is provided in Table 4, encoding a polypeptide ofabout 365 amino acids. The transmembrane segments, determined byhomology to the IL-8 B receptor, are about: TM1 from 39 (leu) to 64(phe); TM2 from 76 (leu) to 96 (ser); TM3 from 111 (leu) to 132 (met);TM4 from 151 (thr) to 176 (phe); TM5 from 207 (gly) to 229 (val); TM6from 246 (val) to 270 (ala); and TM7 from 291 (val) to 319 (leu). Theamino terminal segment is probably an extracellular segment, and theothers would be between TM2 and TM3; and TM4 and TM5; and TM6 and TM7.The intracellular segments should then run between TM1 and TM2; TM3 andTM4, TM5 and TM6, and the carboxy terminus from the end of TM7.Additional processing may occur in a physiological system.

The implication of chemokine receptors in retroviral infection suggestthat the receptor may be critical for infection. Antibodies which blockinfection may be routinely screened, and developed for therapeutic uses.

E. Monocyte/Dendritic Cell Receptor for Chemokine; M/DC Cr

The M/DC CR was isolated from a cDNA library made from human monocytecells cultured for 2.5 to t h in medium containing IFN-γ (10 ng/ml), LPS(1 μg/ml), anti-IL-4 monoclonal antibody (5 μg/ml), and anti-IL-10monoclonal antibody (5 μg/ml). Individual cDNA clones were sequencedusing standard methods, and the M/DC CR sequence was identified andfurther characterized. The nucleotide sequence is provided in Table 5,encoding a polypeptide of about 356 amino acids. The transmembranesegments, should be about as follows: TM1 from 52 (leu) to 76 (val); TM2from 86 (asn) to 107 (ala); TM3 from 117 (ile) to 138 (val); TM4 from157 (val) to 182 (tyr); TM5 from 211 (phe) to 233 (val); TM6 from 251(leu) to 275 (phe); and TM7 from 296 (ile) to 315 (leu). As for the DCCR, the amino terminal segment is probably an extracellular segment, andthe others would be between TM2 and TM3; and TM4 and TM5; and TM6 andTM7. The intracellular segments should then run between TM1 and TM2; TM3and TM4, TM5 and TM6, and the carboxy terminus from the end of TM7.

III. Preparation of Antibodies

Many standard methods are available for preparation of antibodies. Forexample, synthetic peptides may be prepared to be used as antigen,administered to an appropriate animal, and either polyclonal ormonoclonal antibodies prepared. Short peptides, e.g., less than about 10amino acids may be repeated, while longer peptides may be used alone orconjugated to a carrier. For example, with the M/DC CR, animals wereimmunized with peptides corresponding to amino acid sequences from 18-44(starting with LAP and ending with KYD; a fragment towards the aminoterminus) and from 183-204 (starting with KPQ and ending with PAD;corresponding to an extracellular loop), see SEQ ID NO: 13. Highestspecificity will result when the polypeptides are selected from portionswhich are most unique, e.g., not form conserved sequence regions. Theanimals may be used to collect antiserum, or may be used to generatemonoclonal antibodies.

Antiserum was determined useful for ELISA, and will be evaluated forutility as immunoprecipitation or Western blot analysis. Monoclonalantibodies will also be evaluated for those same uses.

The antibodies provided will be useful as immunoaffinity reagents, asdetection reagents, for immunohistochemistry, and as therapeuticreagents.

IV. Assays for Chemotactic Activity of Chemokines

Chemokine proteins are produced, e.g., in COS cells transfected with aplasmid carrying the chemokine cDNA by electroporation. See, Hara, etal. (1992) EMBO J. 10:1875-1884. Physical analytical methods may beapplied, e.g., CD analysis, to compare tertiary structure to otherchemokines to evaluate whether the protein has likely folded into anactive conformation. After transfection, a culture supernatant iscollected and subjected to bioassays. A mock control, e.g., a plasmidcarrying the luciferase cDNA, is used. See, de Wet, et al. (1987) Mol.Cell. Biol. 7:725-757. A positive control, e.g., recombinant murineMIP-1α from R&D Systems (Minneapolis, Minn.), is typically used.Likewise, antibodies may be used to block the biological activities,e.g., as a control.

Lymphocyte migration assays are performed as previously described, e.g.,in Bacon, et al. (1988) Br. J. Pharmacol. 95:966-974. Murine Th2 T cellclones, CDC-25 (see Tony, et al. (1985) J. Exp. Med. 161:223-241) andHDK-1 (see Cherwinski, et al. (1987) J. Exp. Med. 166:1229-1244), madeavailable from R. Coffman and A. O'Garra (DNAX, Palo Alto, Calif.),respectively, are used as controls.

Ca2+ flux upon chemokine stimulation is measured according to thepublished procedure described in Bacon, et al. (1995) J. Immunol.154:3654-3666.

Maximal numbers of migrating cells in response to MIP-1 typically occurat a concentration of 10⁻⁸ M, in agreement with original reports forCD4+ populations of human T cells. See Schall (1993) J. Exp. Med.177:1821-1826. A dose-response curve is determined, preferably giving acharacteristic bell shaped dose-response curve.

After stimulation with C-C chemokines, lymphocytes generally show ameasurable intracellular Ca2+ flux. MIP-1α is capable of inducingimmediate transients of calcium mobilization. Typically, the levels ofchemokine used in these assays will be comparable to those used for thechemotaxis assays (1/1000 dilution of conditioned supernatants).

Retroviral infection assays have also been described, and recentdescription of certain chemokine receptors in retroviral infectionprocesses may indicate that similar roles may apply to the DC CR and/orM/DC CR. See, e.g., Balter (1996) Science 272:1740 (describing evidencefor chemokine receptors as coreceptors for HIV); and Deng, et al. (1996)Nature 381:661-666.

V. Expression Analysis of Chemokine/Receptor Genes

RNA blot and hybridization are performed according to the standardmethod in Maniatis, et al. (1982) Molecular Cloning: A Laboratory ManualCold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. Anappropriate fragment of a cDNA fragment is selected for use as a probe.To verify the amount of RNA loaded in each lane, the substrate membraneis reprobed with a control cDNA, e.g., glyceraldehyde 3-phosphatedehydrogenase (G3PDH) cDNA (Clontech, Palo Alto Calif.).

Analysis of mRNA from the appropriate cell source using the probe willdetermine the natural size of message. It will also indicate whetherdifferent sized messages exist. The messages will be subject to analysisafter isolation, e.g., by PCR or hybridization techniques.

Northern blot analysis may be performed on many different mRNA sources.However, in certain cases, cDNA libraries may be used to evaluatesources which are difficult to prepare. A “reverse Northern” uses cDNAinserts removed from vector, but multiplicity of bands may reflecteither different sized messages, or may be artifact due to incompletereverse transcription in the preparation of the cDNA library. In suchinstances, verification may be appropriate by standard Northernanalysis.

Similarly, Southern blots may be used to evaluate species distributionof a gene. The stringency of washes of the blot will also provideinformation as to the extent of homology of various speciescounterparts.

Tissue distribution, and cell distribution, may be evaluated byimmunohistochemistry using antibodies. Alternatively, in situ nucleicacid hybridization may also be used in such analysis.

A. TECK

The TECK was isolated from a RAG-1 “knockout” mouse. This animal ischaracterized by a great predominance of pro-T or pre-T cells, lackingmore mature T cells after the block point of T cell receptorrearrangement. This suggests a role in very early T cell development,likely expressed by pro-T or pre-T cells, thymic stromal cells, andpossibly macrophages, epithelial, and dendritic cells. This comportswith the observation that tissue distribution studies have not detectedsignificant expression in other organs or tissues. See also, Table 7.

TABLE 7 mTECK mRNA expression in tissues and cells cDNA librariesnorthern blot cell type or tissue neg pos cell type or tissue neg Th2CD4+ T cells X heart X Th1 CD4+ T cells X brain X Lung X spleen X Lcells X lung X RAG-1 KO lung X liver X RAG-1 KO heart X skeletal muscleX RAG-1 KO brain X (+) kidney X RAG-1 KO spleen X testis X RAG-1 KOkidney X thymus RAG-1 KO testis X (+) small intestine RAG-1 KO thymus X(+++) CD4+8- thymocytes R/A X RAG-1 KO liver X (+) CD4-8+ thymocytes R/AX CD4-8- thymocytes X CD4-8- thymocytes R/A X A20-J B-cell X B220+splenocytes R/A X lymphoma BW CD4-8-3- X Thy-1+ splenocytes R/A Xhybridoma pro-T cells X (+) 1G18LA macrophages R/A X pre-T cells Xprimary thymic stroma R/A X 30-R bone marrow X 3D.1 thymic epithelialR/A X stroma D10 T-cell X MTSC-C thymic epithelial X hybridoma CTLLT-cell clone X 30.R bone marrow stroma X peritoneal X macrophagessplenic dendritic X cells Analysis of mTECK mRNA was carried out asdescribed. + to +++ indicates the relative intensity of the signal. R/A:resting or activated.

Species analysis indicated positive signals by hybridization in human,rat, and hamster DNA. Tissue distribution analysis suggests that thegene is expressed in human small intestine, which also is a tissue whichsupports T cell differentiation.

The combination of the structure and distribution of this chemokinesuggests a role in T cell development, which normally occurs in thethymus.

B. MIP-3α

The MIP-3α was identified from a cDNA library made from human monocytesactivated with LPS and IFN-γ, in the presence of anti-IL-10. See, Rossi,et al. (1997) J. Immunology 158:1033-1036, which was published afterpriority dates of this filing. Message of the chemokine has also beendetected in pancreatic islet cells, fetal lung, and hepatic HEPG2 cells,suggesting a physiological role in inflammation or medical conditions insuch organs/tissues.

The gene is expressed in HL-60 (promyelocytic leukemia); S3 (HeLa cell);K562 (chronic myelogenous leukemia); MOLT-4 (lymphblastic leukemia);Raji (Burkitt's lymphoma); SW480 (colorectal adenocarcinoma); A549 (lungcarcinoma); and G361 (melanoma) cell lines, as determined by probing ona tissue blot from CLONTECH. Tissue expression gave a positive signal inlymph node, appendix, peripheral blood lymphocytes, fetal liver, andfetal lung, suggesting a physiological role in inflammation or medicalconditions in such organs/tissues; but no detectable signal in spleen,bone marrow, brain, and kidney.

The main transcript appears to be about 1.2 kb, with two additionaltranscript sizes in fetal lung RNA. Among the various tissues,transcript sizes of 1.8, 2.7, and 4.2 kb were detected.

Positive signals were also detected in the following cDNA libraries:dendritic cells activated with LPS, but not when activated with GM-CSFand IL-4; monocytes treated with LPS, IFN-γ, and anti-IL-10, but notwhen treated with LPS, IFN-γ, and IL-10; and activated PBMC.

These expression data implicate this chemokine in inflammatory responsesupon cell activation. The lymph nodes, appendix, and PBL are sites whereinflammatory processes take place. The MIP-3α may exert its effects onmonocytes and cells involved in inflammatory events. Other structuralfeatures implicate this chemokine in eosinophil and lung physiology,e.g., asthma indications. Thus, an antagonist of the chemokine, e.g., anantibody, may be important for treatment of asthmatic conditions. Also,IL-10 appears to inhibit MIP-3α expression.

The human MIP-3α is a ligand for the DC CR. Thus, a positive controlexists for the Ca++ flux assay for that receptor. This allows for thefurther screening of agonist ligands for the DC CR. Moreover, the DC CRwas isolated from eosinophil cDNA, and observations have been made thateosinophils migrate to MIP-3α in vitro. These suggest that the MIP-3αinteraction with the DC CR is important in recruitment of eosinophils,as occurs with the eotaxin ligand and the CCR3. As such, antagonists ofthe MIP-3α interaction with the DC CR will likely be useful ininhibiting eosinophilia, particularly in the lung, or lung inflammation.These may accompany asthmatic or other pulmonary conditions.

Antagonists to MIP-3α may be made either with antibodies, or otherbinding compositions which inhibit receptor interaction. The antibodiesmay be to the ligand, MIP-3α itself, or to the binding portions of thereceptor, DC CR. Muteins of the chemokine may block receptorinteraction, and with a positive control, chemokine muteins may bescreened for variations which compete with the wild type chemokine atvarious concentrations. See, e.g., Kenakin (1987) PharmacologicalAnalysis of Drug-Receptor Interaction Raven Press, NY; Arunlakshana andSchild (1959) Br. J. Pharmacol. 14:48-58; Black (1989) Science245:486-493; Zurawski, et al. (1986) J. Immunol. 137:3354-3360; Zurawskiand Zurawski (1988) EMBO J. 7:1061-1069; Zurawski and Zurawski (1992)EMBO J. 11:3905-3910; Imler and Zurawski (1992) J. Biol. Chem.267:13185-13190.

C. MIP-3β

The MIP-3β was identified in a cDNA library made from human monocytesactivated with LPS and IFN-γ, in the presence of anti-IL-10. Itsdistribution in other cells and tissues has not been fully determined.

D. Dendritic Cell Receptor for Chemokine; DC CR

The DC CR was isolated from a cDNA library made from a dendritic cellcDNA library. It appears to be expressed in certain T cells, spleen cellsubsets, NK cells, and other cell populations enriched in dendriticcells, including CD1a⁺, CD14⁺, and CD1Aa⁺ cells. It did not give adetectable signal in TF1, Jurkat, MRC5, JY, or U937 cells.

Being found on dendritic cells, its ligand, including the MIP-3α, may beimportant in attracting appropriate cells for the initiation of animmune response. MIP-3α has been shown to be a very potentchemoattractant for dendritic cells. Significant roles of the ligand andreceptor in pulmonary physiology are suggested, both from thedistribution of the receptor and ligand. The receptor may be alsopresent in other cells important in such responses.

E. Monocyte/Dendritic Cell Receptor for chemokine; M/DC CR

The M/DC CR was isolated from a cDNA library made from primary monocytecells activated with LPS and IFN-γ but subtracted with known highabundance genes from those cells. The abundance of this gene is probablyless than about 1% of message from those cells.

Tissue expression gave a positive signal in spleen, PBL, lung, placenta,and small intestine; but no detectable signal in brain, liver, kidney,and muscle. This distribution suggests a hematopoietic role.

There appears to be one main transcript, but the existence of additionalor alternatively spliced messages has not been eliminated.

Positive signals were also detected in the following cDNA libraries:monocytes and dendritic cells; but signals were not detectable in CD8⁺ Tcells, or in either resting or activated splenocytes, gamma-delta Tcells, NK cells, or B cells. Immunohistochemistry will be performed toconfirm absence in the T cell and B cell compartments and to check intonsil, particularly in view of location in spleen and placenta. Therelatively restricted distribution on monocytes and dendritic cellsleads both to its designation, and suggests a functional role in thosecell types, which are important in the initiation of immune responsesthrough their ability to process and present antigen to T cells.

VI. Specific Characterization of TECK

A novel CC chemokine was identified in the thymus of mouse and human andwas designated TECK as Thymus Expressed ChemoKine. TECK has weakhomology with other CC chemokines and maps to mouse chromosome 8.Besides the thymus, mRNA encoding TECK was detected at substantiallevels in the small intestine and at low levels in the liver. The sourceof TECK in the thymus was determined to be thymic dendritic cells, whilein contrast bone marrow-derived dendritic cells do not express TECK. Themurine TECK recombinant protein showed chemotactic activity foractivated macrophages, dendritic cells and thymocytes. We conclude thatTECK represents a novel thymic dendritic cell-specific CC chemokinewhich is possibly involved in T-cell development.

Chemokines belong to a family of small peptides (6-15 kDa) whose bestdescribed biological function is to control the migration of certainleukocyte populations to localized sites of inflammation. Baggiolini, etal. (1994) Adv. in Immun. 55:97-179; Schall and Bacon (1994) Curr OpinImmun 6:865-873; Hedrick and Zlotnik (1996) Curr. Opin. Immunol.8:343-347. In the last few years many new members of the chemokine superfamily have seen the characterized. Initially, new chemokines wereidentified through their chemotactic effects on leukocytes (Baggioliniet al. (1994); Schall and Bacon (1994)) and were isolated mainly fromblood leukocytes or cell lines. More recently, approaches based on theselective cloning of secreted molecules by signal sequence trap(Tashiro, et al. (1993) Science 261:600-603; Imai, et al. (1996) J.Biol. Chem. 271:21514-21521) or on the exploitation of public andprivate databases of expressed sequence tags (EST) throughbioinformatics (Hieshima, et al. (1997) J. Biol. Chem. 272:5846-5853;Patel, et al. (1997) J. Exp. Med. 185:1163-1172; and Rossi, et al.(1997) J. Immunol. 158:1033-1036), have allowed the rapid identificationof novel chemokines based on sequence and structural homologies. Theseapproaches take advantage of the fact that most of the chemokines aresecreted factors whose protein sequence contain four conserved cysteines(Schall (1994) “The Chemokines” pp. 419-460 in Thomson (eds.) TheCytokine Handbook, Academic Press, New York. The CXC or α chemokinefamily has the two first amino-terminal cysteines separated by anon-conserved amino acid. In the CC or β chemokine family, these twocysteines are consecutive. A third type of chemokine, the C or γ family,is represented by lymphotactin, which conserves two cysteines (1 and 3)instead of the original four (Kelner, et al. (1994) Science266:1395-1399). Finally, a recently identified chemokine with threeamino acids separating the first two cysteines defines a fourth CX₃Cfamily (Bazan, et al. (1997) Nature 385:640-644).

Interestingly, some of the new chemokines discovered show a relativelyrestricted pattern of expression (Imai et al. (1996); Hieshima et al.(1997)). It is tempting to suggest that these new approaches may lead tothe discovery of tissue- or cell-specific chemokines. In addition, newbiological evidence for important new roles of chemokines inhaemopoiesis (Cook (1996) J. Leukoc. Biol. 59:61-66; and Nagasawa, etal. (1996) Nature 382:635-638) and the control of viral infectionsincluding HIV (Cocchi, et al. (1995) Science 270:1811-1815; and Cook, etal. (1995) Science 269:1583-1585). Thus, the molecular cloning of novelchemokines through DNA-based strategies may uncover novel proteinsbelonging to the chemokine super family but whose physiological rolegoes beyond the control of inflammation.

In an attempt to identify novel genes involved in T-cell development, weanalyzed a cDNA library from the thymus of Recombinase Activation Gene-1(RAG-1) deficient mice. We identified a novel CC chemokine designatedTECK for Thymus Expressed ChemoKine, based on sequence homology withother known chemokines. We subsequently isolated the human homologue ofTECK. The pattern of expression of TECK mRNA is highly restricted to thethymus and small intestine in both human and mouse. Moreover, in themouse thymus, TECK protein is produced by dendritic cells while splenicdendritic cells do not express TECK mRNA. Recombinant TECK showedchemotactic activity on thymocytes, macrophages, THP-1 cells anddendritic cells, while it was inactive on peripheral lymphocytes andneutrophils. The restricted pattern of expression of TECK together withits biological properties suggest a role for this novel dendriticcell-specific chemokine in T-cell development.

A. Cloning and Structural Analysis of Mouse TECK

A directional cDNA library was made from RAG-1 deficient mouse thymusand analyzed by random sequencing. One of the clones contained an openreading frame with significant homology to previously described CCchemokines. The full-length cDNA contains 1037 bp including an openreading frame of 426 bp encoding a protein of 142 amino acids and willbe identified in this report as mTECK (see Table 1). In the 3′untranslated region, there is one unique polyadenylation signalconsistent with the single mRNA species observed in northern blots. ThemTECK cDNA does not contain any ATTTA transcript destabilization motif(Shaw and Kamrn (1986) Cell 46:659-667). The comparison of the aminoacid sequence of mTECK with previously described murine CC chemokinesdemonstrates the conservation of the four cysteines present in all thesechemokines. However, mTECK shows few additional identities with theseproteins.

B. Cloning and Molecular Characterization of Human TECK

To investigate the possible existence of a gene homologous to mTECK inother mammalian species, a Southern blot with genomic DNA from variousspecies was hybridized with the mTECK cDNA probe. Under high stringencyconditions, hybridizing bands were detected in mouse, rat, hamster andhuman genomic DNAs. Interestingly, a single band was detected in human,suggesting that a single gene encodes for TECK in this species. Themultiple bands present in mouse, rat and hamster could be the result ofa internal EcoRI site within the TECK gene. Alternatively, the TECK genemay have been duplicated in these species.

In order to clone the human homologue of mTECK, a blot of cDNAs from apanel of human cDNA libraries was hybridized with the mTECK cDNA probe.A signal was observed in a fetal small intestine cDNA library. Screeningof this library with the mTECK probe allowed the isolation of severalidentical clones of 1012 bp with an open reading frame of 453 bpencoding a protein of 151 amino acids. This protein had a much higherdegree of homology at the nucleic acid level (71% nucleic acid identityfor the open reading frame and 49.3% amino acid identity) to mTECK thanto other known CC chemokines and was thus designated as hTECK.

C. DNA Sequencing and Bioinformatics

The nucleotide sequence of CRAM was determined using an ABI 377automated sequencer and standard techniques. DNA sequence analyses wereperformed using Sequencher 3.0 (Gene Codes Corporation, Ann Arbor,Mich.) and MacVector 6.0 (Oxford Molecular Group). Comparisons toGenBank databases were performed using the BLAST program on web-basedservers. Sequence alignments and phylogenetic analyses utilized ClustalW1.6 (Higgins, et al. (1996) Methods in Enzymology 266:383) andTreeViewPPC 1.2 (Page (1996) Computer Applications in the Biosciences12:357).

D. Analysis of CRAM mRNA Expression

Multiple-tissue Northern blots were purchased from Clontech (Palo Alto,Calif.). Poly(A)+ RNA from human monocytes was used for RNA blotanalysis. cDNA libraries from human cells (5 μg) in the pSPORT vector(Life Technologies) were digested with SalI and NotI to release cDNAinserts, electrophoresed on 1% agarose gels, and subjected to Southernblot transfer/hybridization. Hybridizations with ³²P-labeled CRAM DNAfragments encoding the C-terminal 144 amino acids of the predicted ORFwere done at 65° C. in ExpressHyb (Clontech, Palo Alto, Calif.) for 2hr, followed by two stringent washes at 50° C. in 0.1×SSC, 0.1% SDS for45 min. Hybridization was detected using a STORM 860 phosphorimager(Molecular Dynamics, Sunnyvale, Calif.). Reverse transcriptase PCR(RT-PCR) was performed with Superscript II reverse transcriptase (LifeTechnologies) and Taq DNA polymerase (Boehringer-Mannheim, Indianapolis,Ind.). PCR was for 35 cycles of 95° C./45 sec, 62° C./30 sec, 72° C./60sec. Primers specific for exon 1 (5′-AGACGCTTCAGAGATCCTCTGGAGGCC; SEQ IDNO: 22) or exon 2 (5′-GAAGCTGCTTCGGGGGGTGAGCAAAC; SEQ ID NO: 23) wereused in conjunction with an exon 3-specific primer(5′-CAAACACAGCAGAGCAGAGTGATGGCACC; SEQ ID NO: 24) for amplification.

E. Chromosomal Localization

PCR was performed on genomic DNA from the 83 cell lines of the StanfordHuman Genome Center G3 radiation hybrid panel (Research Genetics,Huntsville, Ala.) using CRAM primers: (5′-GTGTCCTGGCATGGGTAACAGCC; SEQID NO: 25) and (5′-CGGTGGAATGGTCAGGTTCTTCCC; SEQ ID NO: 26) aspreviously described for the GeneBridge 4 radiation hybrid panel(Samson, et al. (1996) Genomics 36:522). Data correlating the presenceor absence of PCR product to each cell line were entered into theRHserver (Stanford Human Genome Center). Co-localized STSs wereidentified on the human physical map using the Entrez server (NationalCenter for Biotechnology Information).

F. Chemotactic Activities of mTECK Protein

To evaluate the biologic properties of mTECK, a recombinant protein witha N-terminal FLAG peptide was obtained in a bacterial expression system.In some experiments, a recombinant mTECK protein with a C-terminal FLAGwas used and similar results were obtained. Interestingly, mTECK inducedthe migration of mouse thymocytes (FIG. 1A). The optimal response wasobtained with a dose of 10 ng/ml TECK. Cell migration was determined tobe chemotaxis and not chemokinesis through the checkerboard analysis.Furthermore, it is established that chemokines bind to specificreceptors that are coupled through heterotrimeric G proteins tointra-cellular signal-transducing pathways. Murphy (1994) Annu. Rev.Immunol. 12:593-633. To determine whether the chemotaxis of thymocytesinvolved a G protein-coupled receptor, cells were incubated prior to theassay with 10 ng/ml pertussis toxin which ADP-ribosylatesG_(αi)-proteins. Katz, et al. (1992) Nature 360:686-689. Thispre-treatment completely abrogated the chemotactic response ofthymocytes to mTECK (FIG. 1A).

The recombinant mTECK protein also induced the migration of humanmonocytic THP-1 cells activated for 16 hours with IFN-γ (FIG. 1B), whileit was not significantly active on resting THP-1 cells. This experimentshowed that mTECK is active on human cells. In addition, mTECK inducedactivated mouse peritoneal macrophages to migrate as well as highlypurified mouse splenic dendritic cells (FIG. 1B). In all theseexperiments, the optimal dose of mTECK was 10 ng/ml. In contrast, nochemotaxis was observed with bone marrow cells, purified neutrophils,splenic B cells, splenic T cells or IL-2 activated RAG-1 deficient mousesplenocytes lacking mature T and B lymphocytes (Mombaerts, et al. (1992)Cell 68:869-877) and therefore enriched in NK cells. These data areconsistent with the absence of in vivo accumulation of neutrophils,monocytes or lymphocytes 2 and 5 h following an intra-peritonealinjection of 10 μg mTECK. Collectively, these data indicate that TECK isa chemotactic factor for thymocytes, macrophages and dendritic cells.

G. TECK, a Distant Member of the CC Chemokine Family

In this report, we describe the molecular isolation and characterizationof TECK, a novel mouse and human CC chemokine. Analysis of its predictedamino acid sequence showed that TECK is distantly related to previouslydescribed CC chemokines. Conservation of particular amino acids amongmost CC chemokines may be related to their functional importance. Beall,et al. (1992) J. Biol. Chem. 267:3455-3459; and Lusti-Narasimhan, et al.(1995) J. Biol. Chem. 270:2716-2721. In particular, a tyrosine residuebetween the second and third cysteines has been shown to be critical formonocyte chemotaxis (in position 50) (Beall et al. (1992)). While TECKdoes not have a tyrosine at this particular position, it has one inposition 52 that may have the same function, since TECK is chemotacticfor activated monocytes. In addition to these differences in the primarystructure, the gene encoding TECK maps on chromosome 8 in the mouse,unlike most other CC chemokines which are clustered on chromosome 11.This is not the first report of an unusual chromosomal location for a CCchemokine. We have cloned the human CC chemokine MIP-3β and showed thatits gene was on chromosome 9 rather than 17 (Rossi, et al. (1997)), andthe gene encoding the novel human CC chemokine MIP-3α/LARC (Rossi, etal. (1997)) has been mapped on chromosome 2 (Hieshima, et al. (1997)).It is likely that the CC chemokines on chromosome 11 in the mouse and 17in human have been generated through gene duplication of a primordialchemokine. Our results suggest that TECK may have been generated at anearlier stage during evolution. In this regard, the TECK gene may haveevolved to ensure functions similar to other CC chemokines with adistant primary structure but through similar receptor(s) as dictated byits secondary and tertiary structures. Alternatively, the receptor(s)and physiological role of TECK may be unique among chemokines.

H. TECK Expression and Function is Associated with T-Cell Development

We observed that TECK was strongly expressed in the thymus which is theprimary lymphoid organ where T-cell development takes place. Recently,another CC chemokine highly expressed in the thymus, TARC, has beenidentified. Imai, et al. (1996). However, TARC is also expressed in lungand colon as well as activated PBMC (Imai, et al. (1996)) while TECK wasabsent from these tissues. Besides the thymus, numerous reports indicatethat T cell development can occur in the small intestine (Poussier andJulius (1994) Annu. Rev. Immunol. 12:521-553) where TECK is alsoexpressed. Interestingly, the liver has also been suggested to supportT-cell development to some extent (Abo, et al. (1994) Int. Rev. Immunol.11:61-102) and we observed a low TECK expression in a liver cDNAlibrary. These data show that TECK expression correlates with organsthat support T-cell development.

While many molecular and cellular aspects of T-cell differentiation arewell documented, the precise role of chemokines in T-cell development isstill unknown. Recently, it has been shown that the bone marrowstroma-derived CXC chemokine SDF-1 is important for B lymphopoiesis andmyelopoiesis since SDF-1−/− mice are impaired for these functions(Nagasawa, et al. (1996)). Similarly, it is likely that chemokines actat different steps of T-cell differentiation. Chemokines, together withthe expression of appropriate adhesion molecules, may dictate themigration of uncommitted progenitors from the bone marrow to otheranatomic locations. Indeed SDF-1 is chemoattractant for human CD34+progenitor cells. Aiuti, et al. (1997) J. Exp. Med. 185:111-120. Theobservation that TECK is chemoattractant for thymocytes but not formature peripheral T cells suggests that TECK could attract T-cellprogenitors to the thymus. Such populations are very difficult toisolate in sufficient numbers to conduct in vitro chemotaxisexperiments, but we are currently designing new strategies to addressthis important question. In addition, we have not found significantchemotactic activity of TECK on bone marrow cells. SDF-1 was shown to bemuch less potent on CD34+ progenitors from the peripheral blood thanthose from the bone marrow. Aiuti, et al. (1997). It is possible thatthe sensitivity of progenitor cells to TECK would increase as thesecells leave the bone marrow to colonize lymphoid organs. Importantly,intra-thymic maturation is also characterized by a directional migrationfrom the subcapsular region which contains the earliest progenitors tothe cortex and finally to the medulla where thymocytes finish theirmaturation (Boyd, et al. (1993)). It is possible that the secretion ofTECK by medullary dendritic cells may play a role in this directionalmigration. Yet another possibility is that TECK may play a role in theorganization and development of the thymic stroma.

We also showed that TECK is chemotactic for activated macrophages anddendritic cells. These two cell types also play important roles inT-cell development. Through a complex screening process involvingpositive and negative selection events most of the antigenicspecificities randomly generated in the thymus will be eliminated byprogrammed cell death (Janeway (1994) Immunity 1:3-6). The efficientscavenging of dead thymocytes is probably mediated, at least partially,by thymic macrophages and thus TECK could play an important role throughits action on activated macrophages. Further along, T-cells with a highaffinity for self-antigens and thus potentially harmful are eliminatedthrough negative selection (Janeway (1994)). It is believed that thymicdendritic cells are primarily responsible for the negative selection ofthymocytes, therefore playing a major role in the establishment oftolerance. Inaba, et al. (1991) J. Exp. Med. 173:549-559. An efficientmechanism of central tolerance should eliminate T cells potentiallyreactive against auto-antigens which are not expressed in the thymus,such as organ specific auto-antigens. Several known chemokines inducethe migration of dendritic cells and could therefore contribute to theirrecruitment during peripheral immune responses. Sozzani, et al. (1995)J. Immunol. 155:3292-3295; and Xu, et al. (1996) J. Leukoc. Biol.60:365-371. Similarly, dendritic cells presenting organ-specific orother antigens could be recruited to the thymus or the small intestineand induce negative selection of T cells specific for these antigens. Itis possible that thymus- and small intestine-specific chemokines activeon dendritic cells such as TECK could play an important role in theestablishment of tolerance. Thus, TECK could potentially interact atseveral important steps of T-cell development. Future experiments willaim to define the precise role of TECK in T-cell development and otherphysiological processes through the use of genetically modified mice.

I. TECK is Specifically Expressed by Thymic Dendritic Cells

Dendritic cells represent an heterogeneous cell population derived frombone marrow progenitors. They are present in non-lymphoid organs asimmature dendritic cells (such as Langerhans cells in the skin) wherethey display a high ability for antigen capture. Cella, et al. (1997)Curr. Opin. Immunol. 9:10-16. Subsequent to antigen challenge, they willmigrate to secondary lymphoid organs and will acquire a high capacity topresent processed antigens to naive T-cells to initiate a specificimmune response (Cella, et al. (1997)). It has been shown that dendriticcells can derive from CD34+ progenitors cultured in the presence ofGM-CSF and TNF-α (Caux, et al. (1992) Nature 360:258-261; and Caux, etal. (1996) J. Exp. Med. 184:695-706) or from monocytes in the presenceof GM-CSF and IL-4 (Sallusto and Lanzavecchia (1994) J. Exp. Med.179:1109-1118). Interestingly, there is also evidence for a lymphoiddendritic cell precursor in thymus and bone marrow which is able toderive both lymphocytes and dendritic cells in the absence of GM-CSF.Ardavin, et al. (1993) Nature 362:761-763; Galy, et al. (1995) Immunity3:459-473; Marquez, et al. (1995) J. Exp. Med. 181:475-483; and Wu, etal. (1996). These lymphoid-derived dendritic cells may have differentfunctional properties such as a negative regulation of T-cell responsessince they express FasL in the mouse. Suss and Shortman (1996) J. Exp.Med. 183:1789-1796. We found that TECK was expressed at high levels inmouse thymic dendritic cells but was absent in cDNA libraries from mousesplenic dendritic cells or from human dendritic cells generated in vitrofrom CD34+ precursors or monocytes. Interestingly, mTECK mRNA waspresent at a low level in a population of early thymocyte progenitorsstill able to derive dendritic cells (Wu, et al. (1996). Thus, it wouldbe tempting to suggest that TECK could be a specific marker oflymphoid-derived dendritic cells. However, we observed that TECK wasabsent from splenic dendritic cells that likely contain lymphoid-deriveddendritic cells. The expression of TECK mRNA appeared in the spleen ofmice injected with LPS would suggest that peripheral dendritic cells mayexpress TECK upon activation, but we found that TECK was not expressedin cDNA libraries of bone-marrow derived dendritic cells activated withLPS, PMA and ionomycin or IL-1α and TNF-α. It is possible that thenormal expression of TECK is specific for lymphoid-derived dendriticcells or, alternatively, that it is upregulated by very specific stimulipresent in the thymic and intestinal micro-environment underphysiological conditions. Consistent with the latter hypothesis is ourobservation of specific staining of thymic endothelial cells withanti-TECK antibody since we have not been able to find TECK expressionin human HUVEC endothelial cells by northern blot analysis, withoutactivation or following a 16 hour-activation with various combinationsof IL-1, TNF-α, IL-4, IL-7 and oncostatin while some of these stimuliinduce the expression of other CC chemokines in endothelial cells.Rollins and Pober (1991) Am. J. Pathol. 138:1315-1319; Marfaing-Koka, etal. (1995) J. Immunol. 154:1870-1878; Garcia-Zepeda, et al. (1996) J.Immunol. 157:5613-5626; and Garcia-Zepeda, et al. (1996) Nat. Med.4:449-456. Taken together, our data strongly suggest that TECK is anovel chemokine specifically expressed by activated lymphoid-deriveddendritic cells.

Through their function of antigen presentation, dendritic cells playmajor roles in the establishment of tolerance and in the initiation ofan antigen-specific immune response. The use of purified dendritic cellshas been recently proposed in different therapeutic protocols (Cella, etal. (1997)). The discovery of factors with a regulated expression indendritic cells such as the novel CC chemokine TECK will certainlyimprove our knowledge of the biology of dendritic cells and lead to thedesign of relevant in vivo applications.

J. Mice and In Vivo Experimental Procedures

Four to eight week-old and time-pregnant BALB/c mice were purchased fromSimonsen Laboratories (Gilroy, Calif.). RAG-1-deficient mice (Mombaerts,et al. (1992)) were purchased from The Jackson Laboratory (Bar Harbor,Me.). To analyze TECK expression after in vivo activation, variousorgans were recovered from pools of 2 mice 3 hours after intravenous LPSinjection (50 μg LPS in 200 μl PBS or 200 μl PBS for controls).

K. Cell Purification, Culture and Stimulation.

THP-1 cells (TIB-202 from the American Type Culture Collection,Rockville, Md.) were cultured in complete medium which consisted in RPMI1640 medium (JRH BioSciences, Lenexa, Kans.) supplemented with 10% FCS,200 mM L-glutamin, 5×10⁻⁵ M mercaptoethanol, MEM amino-acids andvitamins, sodium bicarbonate, penicillin, streptomycin (all from Sigma,St. Louis, Mo.), and gentamycin (Boehringer, Indianapolis, Ind.). Toobtain activated mouse macrophages, 10 ml of cold PBS were injected intothe peritoneum and the collected cells allowed to adhere to plastic for24 h in complete medium. The adherent fraction, mostly macrophages, wasthen collected. To obtain splenic dendritic cells, a splenocyte cellsuspension was prepared in RPMI 1640 Dutch modified medium (LifeTechnologies, Paisley, Scotland) as described previously in, e.g.,Macatonia, et al. (1987) J. Exp. Med. 166:1654-1667. Splenocytes wereincubated at 37° C. for 16 h and the cell suspension was collected andlaid over Metrizamide (Nycomed Pharma, Oslo, Norway). Aftercentrifugation for 10 min. at 1700×g, the low interface was collectedand stained with anti-Mac-1 (Pharmingen, San Diego, Calif.) and theanti-CD11c N-418 antibodies (Macatonia, et al. (1993) J. Immunol.150:3755-3765). Splenic dendritic cells were sorted by flow cytometry ona FACStar plus cell sorter (Becton Dickinson, Mountain View, Calif.) toa purity greater than 98% upon reanalysis in all the experimentsincluded in this report. To obtain thymic dendritic cells, thymuses werecut in small fragments and resuspended in 10 ml of RPMI-1640+10% FCScontaining 1 mg/ml collagenase and 0.02 mg/ml DNase I (both from SIGMA)and digested with continuous agitation at room temperature for 30 min.(Shortman, et al. (1995) Adv. Exp. Med. Biol. 378:21-29). One ml of 0.1MEDTA pH 7.2 was added for an additional 5 min. Cells were then washed incomplete medium, resuspended in complete medium and overlaid ontoMetrizamide. The thymic dendritic cell-enriched preparation was thenstained with anti-IAd and N-418 antibodies and the dendritic cellssorted by flow cytometry

L. Molecular Cloning of Mouse and Human TECK

The cDNA encoding mouse TECK was obtained by random sequencing of aRAG-1 KO mouse thymic directional cDNA library. Briefly, mRNA wasextracted using RNAzol™ B (Tel-Test, Friendswood, Tex.) and thenoligotex-dT mRNA kit (Quiagen, Chatsworth, Calif.) following themanufacturer's instruction. A directional cDNA library was preparedusing the Superscript™ Plasmid System (Gibco-BRL, Grand Island, N.Y.)and cloned into the pME18s plasmid vector. Sequencing was done using theTaQ DyeDeoxy Terminator Cycle Sequencing kit (Applied Biosystems, FosterCity, Calif.). To determine whether TECK was present in other mammalsincluding human, a Southern blot containing EcoRI digested genomic DNAfrom different species (Bios Laboratories, New Haven, Conn.) washybridized with the full-length mouse TECK cDNA.

The cDNA encoding human TECK was found by screening of a small intestinecDNA library using the full-length mouse TECK cDNA as a probe followingstandard procedures.

M. Northern Blot Analysis of RNA and Southern Blot Analysis of cDNALibraries

All RNA's were isolated from tissues or cells using RNAzol™ B (Tel-Test)and analyzed after electrophoresis in a 1% formaldehyde-agarose gel (10μg/lane). RNA's were then blotted onto a Hybond-N+ nylon membrane(Amersham, Arlington Heights, Ill.). Some northern blots of mRNA werebought from Clontech (Palo Alto, Calif.). To analyze the expression ofTECK in cDNA libraries (obtained from T. MacClanahan, DNAX), 10 μg ofDNA were digested with the appropriate restriction enzymes to releasetheir inserts and analyze by Southern blotting onto nylon membranes.Northern blots and blots of cDNA libraries were hybridized for 16 hoursat 65° C. with a ³²P-labeled probe consisting in the full-length cDNAencoding for mouse or human TECK and then washed and exposed, accordingto standard protocols.

N. Inter Specific Mouse Backcross Mapping

Inter specific backcross progeny were generated by mating (C57B1/6J×M.spretus) F1 females and C57B1/6J males as described, e.g., in Copelandand Jenkins (1991) Trends Genet. 7:113-118. A total of 205 N₂ mice wereused to map the Teck locus. DNA isolation, restriction enzyme digestion,agarose gel electrophoresis, Southern blot transfer and hybridizationwith the full-length mTECK cDNA probe were performed as described, e.g.,in Jenkins, et al. (1982). Fragments of 7.5, 6.9, and 2.5 kb weredetected in Hinci digested C57B1/6J DNA and fragments of 8.8 and 5.4 kbwere detected in HincII digested M. spretus DNA. The presence or absenceof the 8.8 and 5.4 kb HincII M. spretus-specific fragments, whichcosegregated, was followed in backcross mice. A description of theprobes and RFLPs for two of the loci linked to Teck including Insr hasbeen reported previously, e.g., in Ceci, et al. (1990) Genomics 6:72-79.Recombination distances were calculated as described (Green (1981)“Linkage, recombination and mapping” pp. 77-113 in Genetics andProbability in Animal Breeding Experiments, Oxford University Press, NewYork) using the computer program SPRETUS MADNESS.

O. Measurement of TECK mRNA expression by RT-PCR RNA's from sortedthymic dendritic cells or fetal thymuses were prepared with the RNeasytotal RNA kit (Quiagen, Chatsworth, Calif.), following themanufacturer's instructions. First strand cDNAs were generated byreverse transcription with a random hexamer in a 10 μl reaction and 1 μlof this reaction was used as a template for PCR. TECK expression wascompared to the expression of hypoxanthine-guanine phosphoribosyltransferase (HPRT). Primer sequences were as follows: TECK: 5′ primer,5′CCTTCAGGTATCTGGAGAGGAGATC3′ (SEQ ID NO: 20; nucleotides 58-72 of SEQID NO: 1) and 3′ primer, 5′CACGCTTGTACTGTTGGGGTTC3′ (SEQ ID NO: 21;complement of nucleotides 447-468 of SEQ ID NO: 1), HPRT: 5′ primer,5′GTAATGATCAGTCAACGGGGGAC3′ (SEQ ID NO: 17) and 3′ primer,5′CCAGCAAGCTTGCAACCTTAACCA3′ (SEQ ID NO: 18). Samples were submitted to25 cycles of amplification, each composed of 94° C. for 1 min., 57° C.for 30 s and 72° C. for 2 min. PCR products were then separated byelectrophoresis in 2% agarose gels and stained with ethidium bromide.

P. In Situ Hybridization

Biotin-14-CTP labeled sense and antisense riboprobes were generatedusing a non radioactive RNA labeling system (Gibco, Gaithersburg, Md.)and the plasmid PCRII (InVitrogen, Carlsbad, Calif.) containing a 400base pair TECK cDNA fragment inserted by PCR and TA cloning(InVitrogen). Paraffin-embedded tissues were cut in 3-5 μm sections,mounted on slides, baked at 60° C. for one hour, deparaffinized inxylene (Fisher Scientific, Pittsburgh, Pa.) and immersed in 100%ethanol. Sections were then incubated for 10 min at 37° C. in proteinaseK solution (40 mg/ml) (Gibco) in PBS and rinsed for 2 min in PBS at roomtemperature before being refixed in 10% formalin (Fisher Scientific,Pittsburgh, Pa.) in PBS for 1 min. Next, the sections were dehydratedthrough graded solutions of ethanol and air dried. Hybridization wascarried out using the Gibco in situ hybridization and detection systemkit. Vanadyl ribonucleoside complex (Gibco) was added to thehybridization solution (39 mM final). A 0.1 μg/ml concentration of eachprobe was used during an 18 h hybridization at 42° C. Post-hybridizationwashes used room temperature 0.2×SSC. Following detection and substratevisualization, the slides were counterstained with 1% nuclear red stain(Sigma, St. Louis, Mo.).

Q. Immunohistochemistry

A polyclonal antibody specific of a synthetic decapeptide identical tothe C-terminus part of murine TECK (FIG. 1) was prepared in rabbits byResearch Genetics (Huntsville, Ala.). Normal rabbit serum from a pool of50 different animals (Research Genetics) was used as a negative control.To study TECK protein expression in the mouse thymus, 6 μm thickcryostat sections were thaw mounted on organosilicone subbed slides(American Histology Reagent Co., Stockton, Calif.) and fixed in 3%formalin (Fisher Scientific, Springfield, N.J.) in Hank's Balanced SaltSolution with 0.01M HEPES (HBSS-HEPES), pH 7.4, for 15 min at roomtemperature. The sections were sequentially blocked for endogenousbiotin binding using the Vector blocking kit (Vector Laboratories,Burlingame, Calif.) and for endogenous peroxidase activity with a 1%hydrogen peroxide, 0.2M sodium azide solution, in HBSS-HEPES with 0.1%saponin (staining buffer). Non-specific antibody binding sites were thenblocked with 10% normal goat serum (Sigma) in staining buffer. Sectionsprepared as above were first incubated for 18 h at 25° C. with 1/500dilution of polyclonal antibody or control rabbit serum in stainingbuffer. In the second step, the sections were incubated for 1 h at roomtemperature with biotin labeled goat anti-rabbit IgG (2 μg/ml) (VectorLaboratories) in staining buffer and then for 30 min at room temperaturewith the Vectastain Elite ABC Kit (Vector Laboratories) in stainingbuffer. The sections were then rinsed in HBSS-HEPES without saponin.Immunoenzyme tissue staining was revealed with 3,3′-diaminobenzidinetetrahydrochloride (DAB) substrate (0.5 mg/ml) (Sigma) in 0.05M Tris, pH7.4, containing 0.0075% hydrogen peroxide. The substrate reaction wasstopped by rinsing the sections in distilled water. The sections werethen counterstained with Harris' hematoxylin (Shandon Lipshaw,Pittsburgh, Pa.).

The expression of TECK mRNA in murine adult thymus was analyzed by insitu hybridization and revealed a discrete positive non-lymphoidpopulation within the thymus medulla. The expression of TECK protein wasanalyzed by using a polyclonal anti-serum made in a rabbit immunisedwith a peptide that consisted in the last 12 amino-acid of the murineTECK protein sequence. This polyclonal antibody reacts with the murineTECK recombinant protein prepared at DNAX both in ELISA and westernblot. The application of this anti-serum on mouse adult thymic sectionsconfirmed the distribution pattern obtained by in situ hybridization:the cells producing TECK are medullary stromal cells. The precise celltype producing TECK within the mouse thymus was identified, using thesame anti-serum on sorted thymic subsets, as being the thymic dendriticcells.

R. Production of Recombinant Mouse TECK in Escherichia coli and OtherChemokines

Mouse recombinant TECK was produced in E. coli as a N-terminal FLAG(DYKDDDDKL; SEQ ID NO: 19) fusion protein. Briefly, the fusion constructcontaining FLAG followed by the mTECK sequence minus the leader peptide(see Table 1) was obtained by PCR amplification of the TECK cDNA inorder to flank the coding sequence with HindIII and EcoRI sites andsubsequent ligation in the pFLAG.1 vector which contains the FLAGsequence and an OmpA signal sequence. Electro-competent UT 4400 E. coliwere transformed with the pFLAG.1-mTECK plasmid. The cells were grown in2×LB plus 50 μg/ml Ampicillin, induced at an OD. of 2.3 with 400 μM IPTGand harvested. The cell pellet was resuspended in cold lysis buffer (20mM Tris pH 8, 2 mM EDTA, 20% sucrose, 0.1 mg/ml lysozyme, 100 μlBenzonase), homogenized and allowed to sit for 30 min. Then the sameamount of a 1:4 dilution of cold lysis buffer without lysozyme was addedfor 10 more min. The solution was spun and the supernatant was filteredthrough a 0.2 μm membrane and then diluted 1:1 in 50 mM Tris pH 7.5. Thediluted osmotic extract was submitted to chromatography on a Q-sepharosecolumn equilibrated with 50 mM Tris pH 7.5 and eluted with a linear saltgradient. The fractions containing the recombinant protein were pooled.The fractions were then loaded onto a S-sepharose column equilibratedwith 20 mM acetate pH 4.0. The column was eluted with a linear saltgradient and then with a 1.5M NaCl wash that contained the protein.Finally, the eluate was loaded onto a reverse phase column. The columnwas eluted with a linear gradient of 20% to 80% acetonitrile+0.1% TFA.The concentration of the mTECK protein was estimated by Comassie bluestaining and densitometric scanning of a 10% Nu-PAGE gel with lysozymeas a standard. The purity was estimated at 100% by sequencing of theN-terminus of the recombinant protein. Recombinant murine MIP-1α (R&DSystems, Minneapolis, Minn.) and lymphotactin (Hedrick, et al. (1997) J.Immunol. 158:1533-1540) were used as controls.

S. Assay for Chemotaxis

The in vitro migration of cells isolated as described above in responseto TECK or other factors was assessed in a modified Boyden micro chamber(Neuroprobe, Cabin John, Md.) as described previously (Kelner, et al.(1994)). Briefly, factor dilutions in DMEM medium (Gibco) were loaded inthe lower compartment in duplicate and 10⁵ cells in a 50 μl volume ofDMEM were loaded in the upper compartment. The two compartments wereseparated by a 5-μm or 8-μm pore size polycarbonate filter (Nucleopore,Pleasanton, Calif.). After incubation at 37° C. for 80 min (or 120 minfor lymphocytes), the filters were fixed in methanol and stained withFields A and B. Cell migrated on the other side of the membrane werecounted per five high-power fields (100×) under microscope. Thechemotactic index was calculated from the number of cells counted withthe test sample divided by the number of cells counted with mediumalone.

Northern blot analysis was performed of RNA from different organshybridized with the mTECK cDNA probe with or without in vivo LPSstimulation. Hybridizing bands corresponded to the predicted ·1040 bpsize for mTECK mRNA. Significant induction occurred in spleen (withvirtually no background), and in thymus and small intestine (both withhigher background); no signal was detected in either condition forheart, lung, kidney, or liver.

mTECK mRNA expression was analysed in the mouse fetal thymus. RNA's fromfetal thymic lobes were extracted at day 14, 15, 16 and 17 of gestation.Positive RT-PCR signals were detected in each of day 14, 125, 16, and 17samples.

mTECK mRNA expression in thymic dendritic cells was evaluated. Apopulation enriched in thymic dendritic cells was prepared from 15pooled adult thymuses. >99% pure dendritic cells were then sorted byflow cytometry based on their MHC Class II+ N-418+ phenotype. mTECK mRNAwas then analyzed by RT-PCR and a MHC class II+ N-418− population sortedin the same experiment was used as a negative control. The N418+ samplegave a positive signal, while the N418− sample did not.

Expression analysis was performed with hTECK mRNA in different HumanTissues and Cell Types. Southern blots of human cDNA libraries digestedwith the appropriate restriction enzymes were hybridized with the hTECKcDNA probe. A major band hybridizing corresponding to the predictedlength of hTECK mRNA (·1040 bp) was observed with sometimes some otherbands that may represent incomplete cDNAs. Positive signals weredetected in tonsil, fetal spleen, and fetal small intestine. No signalwas detected in activated (with PMA and ionomycin for 12 h) NK cells,activated (anti-CD40 antibody and IL-4 for 6 and 12 h) splenocytes, γδ Tcells, activated (with anti-CD3 and PMA for 6, 12, and 24 h) PBMC, fetaltestis, C+ (elutriated monocytes cultured with IFN-γ and IL-10)monocytes, C− monocytes, 70% pure dendritic cells (CD1α+ dendritic cellpopulation obtained by expansion of CD34+ bone marrow cells with GM-CSFand TNF-α and resting), and DC3 (similar dendritic cell populationstimulated with PMA and ionomycin for 1 and 6 h), DC5 (dendritic cellsobtained by culturing peripheral blood monocytes in the presence of IL-4and GM-CSF), U937 (premonocytic cell line), and CD1α cell lines. Ras KOmouse cDNA again confirmed that the mouse and human genescrosshybridize.

Four independent lines of transgenic mice expressing TECK in the brainhave been made. All animals had neurologic disorders. In addition,several of them suffered severe infections. The consequences of TECKcould be a direct one on brain cells which nature remains to beidentify. Alternatively, since TECK has been shown in vitro to haveeffects on macrophages and dendritic cells which are critical effectorsof immune responses, the overproduction of TECK could lead to distanteffects on these cells at sites of infection. These results suggest thatthe blockade of TECK production in vivo may help to resolve particularpathological processes, in particular infections. The localizationsuggests a physiological role in immunological responses involving thethymus, or in colon/small intestine or gastrointestinal inflammation,e.g., Crohn's disease or inflammatory bowel disease.

VII. Specific Characterization of the M/DC CR(CRAM)

Abbreviations: BAC, bacterial artificial chromosome; bp, base pair; CKR,chemokine receptor; EST, expressed sequence tag; GPR, G-protein-linkedreceptor; PBMC, peripheral blood mononuclear cells; STS, sequence taggedsite.

We describe a novel human gene with high homology to CC- or β-chemokinereceptors (CKRs). This putative CKR, CRAM, is most similar to humanCCR1, with 46% amino acid identity and 65% similarity. CRAM is encodedby at least two alternatively spliced 1.5 and 1.8 kb mRNAs which specifyat least two proteins differing by 12 amino acids at the N-terminus(CRAM-A and CRAM-B). CRAM mRNA was detected mainly in lymphoid tissuesand expressed in activated monocytes, but not in B- or T-lymphocytes.CRAM mRNA expression was increased upon stimulation with IFNγ and LPSbut was not detectably inhibited by interleukin-10. CRAM was localizedto the β-CKR cluster at chromosome 3p21 and physically linked to theCCR2 and CCR5 genes. In view of its similarity and genomic linkage toβ-CKRs and restricted expression pattern, CRAM may play an importantrole in immune function. The existence of CRAM with alternativeN-termini suggests a mechanism for altering ligand specificity andpossibly signalling capacity of a single CKR.

Chemokines play critical roles in the chemoattraction and activation ofleukocytes (Premack and Schall (1996) Nat Med 2:1174; Murphy (1996)Cytokine Growth Factor Rev 7:47; and Furie and Randolph (1995) Am Pathol146:1287), and have been divided into four families, based on thespacing of the first two of (usually) four conserved cysteine residues.The α chemokines, with a C-X-C motif, include IL-8, MIP-2α, GROG, andENA-78. The β chemokines (C-C motif), include MIP-1α, MCP-1, TARC, andRANTES. Recently, two new chemokine families have been defined bylymphotactin (γ) and CX₃Ckine (δ). Lymphotactin has only a singlecysteine residue at the corresponding location for the C-C or C-X-Cmotif. Kelner and Zlotnik. (1995) J Leukoc Biol 57:778; Kennedy, et al.(1995) J Immunol 155:203. CX₃Ckine contains two cysteines separated bythree intervening amino acids, and is tethered to the cell membrane viaa long carboxy-terminal tail of mucin-like repeats. Bazan, et al. (1997)Nature 385:640.

Receptors for chemokines (CKRs) are G-protein coupled receptors (GPRs)with seven transmembrane domains. Novel CKRs have been identified byexpression cloning of receptors binding a particular chemokine ligand(Holmes, et al. (1991) Science 253:1280) or mediating HIV fusion (Feng,et al. (1996) Science 272:872), by PCR using degenerate primers specificfor conserved regions (Meyer, et al. (1996) J Biol Chem 271:14445;Ponath, et al. (1996) J Exp Med 183:2437; Daugherty, et al. (1996) J ExpMed 183:2349; Kurihara and Bravo (1996) J Biol Chem 271:11603; Power, etal. (1995) J Biol Chem 270:19495; Napolitano, et al. (1996) J Immunol157:2759; and Raport, et al. (1996) J Leukoc Biol 59:18), and by randomsequencing efforts followed by sequence analysis. While nearly 30CKR-like genes have been cloned from mammals and mammalian viruses, only17 have been shown to bind identified chemokines. Thus, a substantialnumber of CKR-like molecules remain “orphan receptors.” Most CKRs withexperimentally identified ligands bind to more than one ligand. IL-8receptor B (CXCR2) binds to the α chemokines IL-8, NAP-2, and MGSA(Suzuki, et al. (1994) J Biol Chem 269:18263), whereas human CCR5 bindsthe β chemokines RANTES, MIP-1α, and MIP-1β (Raport, et al. (1996) JBiol Chem 271:17161; and Alkhatib, et al. (1996) Science 272:1955).

We have used cDNA library subtraction to isolate genes which are inducedby monocyte activation. We thereby isolated a cDNA clone from asubtracted library enriched for monocyte activation-specific cDNAs thatshows considerable homology to CC- or β-CKRs and maps within the β-CKRcluster on human chromosome 3p21. Expression of this gene was detectedin several lymphoid tissues and in activated monocytes (but notlymphocytes). We provisionally designate this gene CRAM, for chemokinereceptor of activated monocytes. CRAM is expressed as at least twoalternatively spliced mRNAs encoding CKRs with different N-terminalamino acid sequences, suggesting a possible novel mechanism forregulation of CKR ligand specificity.

A. Cell Cultures and cDNA Library Construction

Human PBMC were purified by density gradient centrifugation on Ficoll(Pharmacia Biotech Inc., Piscataway, N.J.) using standard procedures.Monocytes were enriched from PBMC by adherence to tissue culture flasksand cultured in DMEM+10% FCS. Monocytes were activated by culture with100 ng/ml IFNγ (R & D Systems Inc., Minneapolis, Minn.) and 1 μg/ml LPS(Life Technologies, Grand Island, N.Y.) for 1-15 hr. Total RNA wasprepared by guanidinium isothiocyanate lysis followed by poly(A)+ RNAselection using the OLIGOTEX kit (QIAGEN Inc., Chatsworth, Calif.). cDNAlibraries containing >2×10⁶ independent clones were constructed usingthe SuperScript cDNA Kit (Life Technologies).

B. cDNA Library Subtractions

Subtracted cDNA libraries (activated monocytes minus resting PBMC) wereconstructed. See, e.g., Hara, et al. (1994) Blood 84:189; and Kennedy,et al. (1996) J Interferon Cytokine Res 16:611. The major cDNA speciespresent in the subtracted library were then added (1 μg each) to theresting PBMC cDNA library (150 μg); this mixture was used as the drivercDNA for a second round of subtraction using 5 μg of the activatedmonocyte cDNA library to enrich for induction-specific cDNAs which wereless abundantly expressed.

C. DNA Sequencing and Bioinformatics

The nucleotide sequence of CRAM was determined using an ABI 377automated sequencer and standard techniques. DNA sequence analyses wereperformed using Sequencher 3.0 (Gene Codes Corporation, Ann Arbor,Mich.) and MacVector 6.0 (Oxford Molecular Group). Comparisons toGenBank databases were performed using the BLAST program on web-basedservers. Sequence alignments and phylogenetic analyses utilized ClustalW1.6 (Higgins, et al. (1996) Methods in Enzymology 266:383) andTreeViewPPC 1.2 (Page (1996) Computer Applications in the Biosciences12:357).

D. Analysis of CRAM mRNA Expression

Multiple-tissue Northern blots were purchased from Clontech (Palo Alto,Calif.). Poly(A)+ RNA from human monocytes was used for RNA blotanalysis. cDNA libraries from human cells (5 μg) in the pSPORT vector(Life Technologies) were digested with SalI and NotI to release cDNAinserts, electrophoresed on 1% agarose gels, and subjected to Southernblot transfer/hybridization. Hybridizations with ³²P-labeled CRAM DNAfragments encoding the C-terminal 144 amino acids of the predicted ORFwere done at 65° C. in ExpressHyb (Clontech, Palo Alto, Calif.) for 2hr, followed by two stringent washes at 50° C. in 0.1×SSC, 0.1% SDS for45 min. Hybridization was detected using a STORM 860 phosphorimager(Molecular Dynamics, Sunnyvale, Calif.). Reverse transcriptase PCR(RT-PCR) was performed with Superscript II reverse transcriptase (LifeTechnologies) and Taq DNA polymerase (Boehringer-Mannheim, Indianapolis,Ind.). PCR was for 35 cycles of 95° C./45 sec, 62° C./30 sec, 72° C./60sec. Primers specific for exon 1 (5′-AGACGCTTCAGAGATCCTCTGGAGGCC; SEQ IDNO: 22) or exon 2 (5′-GAAGCTGCTTCGGGGGGTGAGCAAAC; SEQ ID NO: 23) wereused in conjunction with an exon 3-specific primer(5′-CAAACACAGCAGAGCAGAGTGATGGCACC; SEQ ID NO: 24) for amplification.

E. Chromosomal Localization

PCR was performed on genomic DNA from the 83 cell lines of the StanfordHuman Genome Center G3 radiation hybrid panel (Research Genetics,Huntsville, Ala.) using CRAM primers: (5′-GTGTCCTGGCATGGGTAACAGCC; SEQID NO: 25) and (5′-CGGTGGAATGGTCAGGTTCTTCCC; SEQ ID NO: 26) aspreviously described for the GeneBridge 4 radiation hybrid panel(Samson, et al. (1996) Genomics 36:522). Data correlating the presenceor absence of PCR product to each cell line were entered into theRHserver (Stanford Human Genome Center). Co-localized STSs wereidentified on the human physical map using the Entrez server (NationalCenter for Biotechnology Information).

F. cDNA Cloning of CRAM

We employed subtractive hybridization to identify genes induced inmonocytes upon activation by IFNγ and LPS. An activated monocyte cDNAlibrary was first subtracted against a resting PBMC cDNA library. Sevenprominent induced cDNAs thus identified were mixed with the resting PBMClibrary, which was then used as “driver” in another subtraction togenerate a new library containing less abundantly expressed,induction-specific cDNAs. More than 100 clones were isolated from thissecond-round subtracted library, representing 55 unique cDNAs, 25 ofwhich did not correspond to known cDNAs from the non-redundant sectionof GenBank. One of these clones contained a 1.5 kb insert encoding alarge open reading frame with strong homology to all five known humanβ-CKRs. We designated this cDNA CRAM (chemokine receptor of activatedmonocytes; or M/DC CR).

G. Sequence Analysis of CKRs

A phylogenetic analysis of CKRs and related gene sequences revealed twomajor clades or phylogenetic groups, with several receptors remainingunclustered outside these two groups. Interestingly, the two groupscorrelated with known ligand specificities: the α-CKR IL-8RA, IL-8RB,and fusin cluster in a single clade, while β-CKR CCR1 through CCR5 allcluster in a second clade. Of the seven receptors that do not fall intoeither group, one (DARC) is a promiscuous CKR that binds several α- andβ-chemokines (Neote, et al. (1993) J Biol Chem 268:12247).

The 1536 bp CRAM cDNA encodes an ORF with a predicted size of about 356amino acids. Phylogenetic analysis showed that CRAM was most closelyrelated to β-CKRs, exhibiting strongest homology to CCR1 (46% identityand 65% similarity), and the least to CCR4, with only 33% identity and48% similarity. Three other human orphan receptors V28, TER1, and GPR5also group with β-CKRs, and like CRAM, may be receptors for known or yetto be identified β chemokines.

The two most highly conserved regions among CCR1 through CCR5 are intransmembrane region 2 (YLLNLAISDLLF; “TM2”) and immediately aftertransmembrane region 3 (IDRYLAIVHAVF; “DRY-box”). These two 12-aminoacid segments are invariant among CCR1 through CCR4; CCR5 shares 22 ofthese 24 residues. These regions are sometimes conserved among othermammalian GPR and have been used for degenerate primer PCR to clone newCKRs. CRAM is divergent in these regions (9 out of 12 amino acids inTM2; 4 out of 12 in the DRY-box), which may explain why such approacheshave failed to identify CRAM. The DRY-box is in one of the threeintracellular loops, and is thought to play a role in binding toheterotrimeric G proteins (Damaj, et al. (1996) FASEB J 10:1426).Because of the divergence of CRAM from the other β-CKRs in theseregions, it may interact with a different subset of G protein subunits,possibly transducing a signal different from that induced via otherβ-CKRs.

While human CKR genes have been localized to several differentchromosomes, the β-CKR genes CCR1, CCR2, CCR3, and CCR5 all cluster in a350 kb region at chromosome 3p21.3 (Samson, et al. (1996) Genomics36:522). CCR4 and the orphan receptors TER1 and GPR5 are also located inthis 3p21 region Napolitano, et al. (1996) J Immunol 157:2759; Samson,et al. (1996) Genomics 36:522; Heiber, et al. (1995) DNA Cell Biol14:25). We determined the chromosomal location of CRAM. The Stanford G3panel of radiation hybrids was used as templates for PCR reactions withCRAM-specific primers. Among the 83 different hybrids, 11 contained theCRAM gene as assessed by PCR. CRAM co-localized with STS D3S3888, whichis located at chromosome 3p21.3. Confirmation of this result wasobtained from the recently completed sequence of the 143 kb BAC clone110p12 from the 3p21 region (GenBank accession U95626); this BACcontains the loci CCR2, CCR5, and CRAM.

A related but different CRAM cDNA was also isolated from an activatedmonocyte library by random sequencing. Comparing the two forms of CRAMto the genomic sequence revealed the existence of two short exons(corresponding to 95750-96064 bp and 96186-96256 bp on BAC 110p12),followed by a large third exon (96630-98093 bp) that contains almost theentire ORF for CRAM. These two CRAM cDNAs consist of either exon 2 andexon 3 (1536 bp), or exon 1 and exon 3 (1780 bp). Exon 2 contributes 12amino acids in frame with exon 3 to form the entire 356 residuepolypeptide (CRAM-A). As exon 1 has no methionine in frame with the ORFin exon 3, the translated protein from this splice variant would startwith Met-13, resulting in an N-terminally truncated protein of 344 aminoacids (CRAM-B).

H. Expression of CRAM mRNA

RNA blot analysis showed expression largely restricted to lymphoidtissues. Prominent expression of CRAM mRNA was observed in spleen, lymphnode, thymus, bone marrow, and fetal liver. Very little expression wasdetected in brain, liver, muscle, kidney, pancreas, or PBL, withmoderate signals in heart, placenta, lung, and appendix. This pattern ofexpression was similar to that of the CKR-like gene TER1 (Napolitano, etal. (1996) J Immunol 157:2759), but quite different from the relatedorphan receptor genes V28 and blr1 (Forster, et al. (1996) Cell 87:1037;and Raport, et al. (1995) Gene 163:295).

Data from various hematopoietic cell types showed no evidence for CRAMexpression in resting or activated lymphocytes, or in splenocytes. CRAMmRNA was also not detected in resting monocytic cell lines, but wasstrongly expressed in primary monocytes and THP-1 cells upon activationwith IFNγ and LPS. Both CRAM-A and CRAM-B mRNAs were induced, asdetected by RT-PCR using exon 1- and exon 2-specific primers. Incontrast to several other monocyte activation-induced genes, such asmonokines (TNFα, IL-1, IL-6) and some cell-surface antigens (Ho andMoore. (1994) Therapeutic Immunology 1:173). CRAM mRNA expression wasnot detectably inhibited by IL-10. Thus, CRAM expression in monocytesmay be regulated via a different mechanism compared to that of severalother activation-induced genes.

While most CKR genes lack introns, the genes for human CCR2 and mouseCXCR4 (fusin) both contain at least two exons and both have twoalternatively spliced forms. CCR2A and CCR2B differ in the C-terminus(Charo, et al. (1994) Proc. Natl. Acad. Sci. U.S.A. 91:2752), whereasCXCR4 has two forms that differ by two amino acids at the N-terminus(Heesen, et al. (1997) J. Immunol. 158:3561). The two forms of CCR2 haveidentical ligand specificities, but differ with respect to which G_(α)subunits they can couple (Kuang, et al. (1996) J. Biol. Chem. 271:3975);the two forms of CXCR4 can both serve as functional CKRs for SDF-1α(Heesen, et al. (1997) J. Immunol. 158:3561), although their ligandspecificities and interactions with HIV have not been fullycharacterized. The N-terminal sequence of CKRs, along with portions ofthe extracellular loops, is known to play a key role in ligand bindingand possibly receptor activation (Ahuja, et al. (1996) J. Biol. Chem.271:225; Lu, et al. (1995) J. Biol. Chem. 270:26239; Horuk (1994)Immunol. Today 15:169; Wells, et al. (1996) J Leukoc Biol 59:53; andHebert, et al. (1993) J. Biol. Chem. 268:18549). This region of CKR isalso important for HIV fusion (Rucker, et al. (1996) Cell 87:437.),which is antagonized by chemokine ligands (Paxton, et al. (1996) NatureMed. 2:412; and Cocchi, et al. (1995) Science 270:1811). Thus it ispossible that CRAM-A and CRAM-B may exhibit different but likelyoverlapping ligand specificities. Regulated expression of alternativeforms of a single CKR, combined with possible modulation of specificityof ligand-receptor interaction by chemokine-proteoglycan interaction(Graham, et al. (1996) The EMBO J. 15:6506; and Witt and Lander (1994)Curr. Biol. 4:394), might control the spectrum of chemokines to which aparticular cell could respond. In addition, these observations mayprovide one possible explanation of non-reciprocal desensitizationphenomena observed with, for example, the chemokines RANTES, MIP-1α, andMCAF (Wang, et al. (1993) J Exp Med 177:699).

The similarity of CRAM to the other β-CKRs, its chromosomal localizationin the β-CKR gene cluster, and induction of its expression in monocytesupon activation all argue that CRAM may play an important role inregulation of immune function.

VIII. Screening for Receptor/Ligand

Labeled reagent is useful for screening of an expression library madefrom a cell line which expresses a chemokine or receptor, asappropriate. Standard staining techniques are used to detect or sortintracellular or surface expressed ligand, or surface expressingtransformed cells are screened by panning. Screening of intracellularexpression is performed by various staining or immunofluorescenceprocedures. See also, e.g., McMahan, et al. (1991) EMBO J. 10:2821-2832.

For example, on day 0, precoat 2-chamber permanox slides with 1 ml perchamber of fibronectin, 10 ng/ml in PBS, for 30 min at room temperature.Rinse once with PBS. Then plate COS cells at 2−3×10⁵ cells per chamberin 1.5 ml of growth media. Incubate overnight at 37° C.

On day 1 for each sample, prepare 0.5 ml of a solution of 66 μg/mlDEAE-dextran, 66 μM chloroquine, and 4 μg DNA in serum free DME. Foreach set, a positive control is prepared, e.g., of huIL-10-FLAG cDNA at1 and 1/200 dilution, and a negative mock. Rinse cells with serum freeDME. Add the DNA solution and incubate 5 hr at 37° C. Remove the mediumand add 0.5 ml 10% DMSO in DME for 2.5 min. Remove and wash once withDME. Add 1.5 ml growth medium and incubate overnight.

On day 2, change the medium. On days 3 or 4, the cells are fixed andstained. Rinse the cells twice with Hank's Buffered Saline Solution(HBSS) and fix in 4% paraformaldehyde (PFA)/glucose for 5 min. Wash 3×with HBSS. The slides may be stored at −80° C. after all liquid isremoved. For each chamber, 0.5 ml incubations are performed as follows.Add HBSS/saponin (0.1%) with 32 μl/ml of 1M NaN₃ for 20 min. Cells arethen washed with HBSS/saponin 1×. Add antibody complex to cells andincubate for 30 min. Wash cells twice with HBSS/saponin. Add secondantibody, e.g., Vector anti-mouse antibody, at 1/200 dilution, andincubate for 30 min. Prepare ELISA solution, e.g., Vector Elite ABChorseradish peroxidase solution, and preincubate for 30 min. Use, e.g.,1 drop of solution A (avidin) and 1 drop solution B (biotin) per 2.5 mlHBSS/saponin. Wash cells twice with HBSS/saponin. Add ABC HRP solutionand incubate for 30 min. Wash cells twice with HBSS, second wash for 2min, which closes cells. Then add Vector diaminobenzoic acid (DAB) for 5to 10 min. Use 2 drops of buffer plus 4 drops DAB plus 2 drops of H₂O₂per 5 ml of glass distilled water. Carefully remove chamber and rinseslide in water. Air dry for a few minutes, then add 1 drop of CrystalMount and a cover slip. Bake for 5 min at 85-90° C.

Alternatively, the binding compositions are used to affinity purify orsort out cells expressing the ligand or receptor. See, e.g., Sambrook,et al. or Ausubel et al.

All references cited herein are incorporated herein by reference to thesame extent as if each individual publication or patent application wasspecifically and individually indicated to be incorporated by reference.

Many modification an variations of this invention can be made withoutdeparting from its spirit and scope, as will be apparent to thoseskilled in the art. The specific embodiments described herein areoffered by way of example only, and the invention is to be limited onlyby the terms of the appended claims, along with the full scope of theequivalents to which such claims are entitled.

1. A substantially pure or isolated polypeptide comprising a segmentexhibiting sequence homology to a corresponding portion of a matureprotein selected from the group consisting of: i) TECK; ii) MIP-3α; iii)MIP-3β; iv) DC CR; and v) M/DC CR; wherein said homology is at leastabout 70% identity and said portion is at least about 25 amino acids. 2.The protein of claim 1, further comprising a second segment exhibiting:a) at least about 90% identity over at least 9 amino acids; or b) atleast about 80% identity over at least 17 amino acids.
 3. Thepolypeptide of claim 1, wherein said polypeptide: a) is from a warmblooded animal selected from the group of birds and mammals, including amouse or human; b) comprises a natural sequence from Tables 1 through 5;c) exhibits a post-translational modification pattern distinct from anatural form of said polypeptide; d) is made by expression of arecombinant nucleic acid; e) comprises synthetic sequence; f) isdetectably labeled; g) is conjugated to a solid substrate; h) isconjugated to another chemical moiety; i) is a fusion protein; j) is ina denatured conformation, including detergent denaturation; k) furthercomprises an epitope tag; l) is an immunogenic polypeptide; m) has adefined homogeneous molecular weight; n) is useful as a carbon source;o) is an allelic variant of SEQ ID NO: 2, 4, 6, 8, 10, or 12; p) is a3-fold or less substituted form of a natural sequence; q) is in asterile composition; r) is in a buffered solution or suspension; s) isin a regulated release device; t) comprises a post-translationalmodification; u) is in a cell; or v) is in a kit which further comprisesinstructions for use or disposal of reagents therein.
 4. An isolated orrecombinant nucleic acid encoding said protein of claim 1, where saidportion consists of sequence from the coding region of SEQ ID NO: 1, 3,5, 7, 9, or
 11. 5. The nucleic acid of claim 4, wherein said nucleicacid: a) exhibits at least about 80% identity to a natural cDNA encodingsaid segment; b) is in an expression vector; c) further comprises apromoter; d) further comprises an origin of replication; e) is from anatural source; f) is detectably labeled; g) comprises syntheticnucleotide sequence; h) is less than 6 kb; i) is from a mammal; j)comprises a natural full length mature coding sequence; k) is in a kit,which also comprises instructions for use or disposal of reagentstherein; l) is a specific hybridization probe for a gene encoding saidprotein; m) is a PCR product; or n) is in a cell.
 6. A method of using apurified nucleic acid of claim 5, comprising a step of expressing saidnucleic acid to produce a protein.
 7. An isolated or recombinant nucleicacid which encodes at least eight consecutive residues of SEQ ID NO: 2,4, 6, 8, 10, or
 12. 8. The nucleic acid of claim 7, which encodes atleast: a) twelve consecutive residues from SEQ ID NO: 2, and furthercomprises a coding sequence of at least 17 nucleotides from SEQ ID NO:1; b) twelve consecutive residues from SEQ ID NO: 4, and furthercomprises a coding sequence of at least 17 nucleotides from SEQ ID NO:3; c) twelve consecutive residues from SEQ ID NO: 6, and furthercomprises a coding sequence of at least 17 nucleotides from SEQ ID NO:5; d) twelve consecutive residues from SEQ ID NO: 8, and furthercomprises a coding sequence of at least 17 nucleotides from SEQ ID NO:7; e) twelve consecutive residues from SEQ ID NO: 10, and furthercomprises a coding sequence of at least 17 nucleotides from SEQ ID NO:9; or f) twelve consecutive residues from SEQ ID NO: 12, and furthercomprises a coding sequence of at least 17 nucleotides from SEQ ID NO:11.
 9. The nucleic acid of claim 7, wherein said nucleic acid: a)exhibits at least about 80% identity to a natural cDNA encoding saidsegment; b) is in an expression vector; c) further comprises a promoter;d) further comprises an origin of replication; e) encodes a 3-fold orless substituted sequence from a natural sequence; f) is from a naturalsource; g) is detectably labeled; h) comprises synthetic nucleotidesequence; i) is less than 6 kb; j) is from a mammal; k) is attached to asolid substrate, including in a Southern or Northern blot; l) comprisesa natural full length coding sequence; m) is in a cell; or n) is in adetection kit, which also comprises instructions for use or disposal ofreagents therein.
 10. A nucleic acid which hybridizes under stringentwash conditions of 55° C. and less than 150 mM salt to the nucleic acidof claim
 7. 11. The nucleic acid of claim 10, which exhibits at leastabout 85% identity over a stretch of at least about 30 nucleotides to aprimate sequence of SEQ ID NO: 1, 3, 5, 7, 9, or
 11. 12. The nucleicacid of claim 10, wherein: a) said identity is at least 90%; or b) saidstretch is at least 75 nucleotides.
 13. The nucleic acid of claim 10,wherein: a) said identity is at least 95%; or b) said stretch is atleast 100 nucleotides.
 14. A binding compound comprising an antigenbinding fragment from an antibody which binds to a protein of claim 1.15. The binding compound of claim 14, wherein: a) said polypeptide is amouse or human protein; b) said antibody is raised against a maturepeptide sequence of Tables 1 through 5; c) said antibody is a monoclonalantibody; d) said binding compound is attached to a solid substrate; e)said binding compound is in a sterile composition; f) said bindingcompound binds to a denatured antigen, including a detergent denaturedantigen; g) said binding compound is detectably labeled; h) said bindingcompound is an Fv, Fab, or Fab2 fragment; i) said binding compound isconjugated to a chemical moiety; j) said binding compound is in adetection kit which also comprises instructions for use or disposal ofreagents therein.
 16. A cell which makes said antibody of claim
 14. 17.A method of purifying a polypeptide using a binding compound of claim 14to specifically separate said polypeptides from others.
 18. A method ofgenerating an antigen-binding compound complex comprising the step ofcontacting a sample comprising said antigen to a sample comprising abinding compound of claim
 14. 19. A method of modulating physiology ordevelopment of a cell expressing a receptor for a chemokine selectedfrom the group selected from: a) TECK; b) MIP-3α; or c) MIP-3β;comprising contacting said cell with a composition comprising: i) anagonist or mutein of said chemokine; or ii) an antibody antagonist ofsaid chemokine.
 20. The method of claim 19, wherein said cell is amacrophage or lymphocyte.
 21. The method of claim 19, wherein saidphysiology is selected from: a) a cellular calcium flux; b) achemoattractant response; c) cellular morphology modification responses;d) phosphoinositide lipid turnover; or e) an antiviral response.
 22. Themethod of claim 19, wherein: a) said receptor is DC CR and saidchemokine is MIP-3α; b) said physiology is pulmonary physiology; or c)said cell is an eosinophil.